Drug Database · Clinicians

Lenalidomide

Brands (13) Lenagen, Lenalid 10, Lenalid 5…Show all

US brand (reference label): Revlimid; not a Philippine-registered brand.

Thalidomide Analog US FDA class
Immunosuppressant PH FDA category

Rx · Prescription drug18 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 5fa97bf5-28a2-48f1-8955-f56012d296be, version date March 24, 2023 (Revlimid · Celgene Corporation). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Multiple myeloma (MM), in combination with dexamethasone
  • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
  • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities
  • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
  • Previously treated follicular lymphoma (FL), in combination with a rituximab product
  • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with:

  • Multiple myeloma (MM), in combination with dexamethasone (1.1).
  • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) (1.1).
  • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2).
  • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3).
  • Previously treated follicular lymphoma (FL), in combination with a rituximab product (1.4).
  • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product (1.5). Limitations of Use:
  • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Follicular Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). 1.5 Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). 1.6 Limitations of Use REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)].

Contraindications

4 CONTRAINDICATIONS

  • Pregnancy (Boxed Warning, 4.1, 5.1, 8.1).
  • Demonstrated severe hypersensitivity to lenalidomide (4.2, 5.9, 5.15). 4.1 Pregnancy REVLIMID can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning]. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1, 5.2), Use in Special Populations (8.1, 8.3)]. 4.2 Severe Hypersensitivity Reactions REVLIMID is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9, 5.15)].
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

  • MM combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles. (2.1).
  • MM maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles (2.1).
  • MDS: 10 mg once daily (2.2).
  • MCL: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles (2.3).
  • FL or MZL: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to 12 cycles (2.4).
  • Renal impairment: Adjust starting dose based on the creatinine clearance value (2.6).
  • For concomitant therapy doses, see Full Prescribing Information (2.1, 2.4, 14.1, 14.4).
2.1 Recommended Dosage for Multiple Myeloma

2.1 Recommended Dosage for Multiple Myeloma REVLIMID Combination Therapy The recommended starting dose of REVLIMID is 25 mg orally once daily on Days 1-21 of repeated 28-day cycles in combination with dexamethasone. Refer to Section 14.1 for specific dexamethasone dosing. For patients greater than 75 years old, the starting dose of dexamethasone may be reduced [see Clinical Studies (14.1)].

Treatment should be continued until disease progression or unacceptable toxicity. In patients who are not eligible for auto-HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a REVLIMID-containing therapy [see Warnings and Precautions (5.12)].

Dose Adjustments for Hematologic Toxicities During MM Treatment Dose modification guidelines, as summarized in Table 1 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to REVLIMID. Table 1: Dose Adjustments for Hematologic Toxicities for MM Platelet counts Thrombocytopenia in MM When Platelets Recommended Course Days 1-21 of repeated 28-day cycle Fall below 30,000/mcL Interrupt REVLIMID treatment, follow CBC weekly Return to at least 30,000/mcL Resume REVLIMID at next lower dose.

Do not dose below 2.5 mg daily For each subsequent drop below 30,000/mcL Interrupt REVLIMID treatment Return to at least 30,000/mcL Resume REVLIMID at next lower dose. Do not dose below 2.5 mg daily Absolute Neutrophil counts (ANC) Neutropenia in MM When Neutrophils Recommended Course Days 1-21 of repeated 28-day cycle Fall below 1,000/mcL Interrupt REVLIMID treatment, follow CBC weekly Return to at least 1,000/mcL and neutropenia is the only toxicity Resume REVLIMID at 25 mg daily or initial starting dose Return to at least 1,000/mcL and if other toxicity Resume REVLIMID at next lower dose.

Do not dose below 2.5 mg daily For each subsequent drop below 1,000/mcL Interrupt REVLIMID treatment Return to at least 1,000/mcL Resume REVLIMID at next lower dose. Do not dose below 2.5 mg daily REVLIMID Maintenance Therapy Following Auto-HSCT Following auto-HSCT, initiate REVLIMID maintenance therapy after adequate hematologic recovery (ANC at least 1,000/mcL and/or platelet counts at least 75,000/mcL).

The recommended starting dose of REVLIMID is 10 mg once daily continuously (Days 1-28 of repeated 28-day cycles) until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated. Dose Adjustments for Hematologic Toxicities During MM Treatment Dose modification guidelines, as summarized in Table 2 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to REVLIMID.

Table 2: Dose Adjustments for Hematologic Toxicities for MM Platelet counts Thrombocytopenia in MM When Platelets Recommended Course Fall below 30,000/mcL Interrupt REVLIMID treatment, follow CBC weekly Return to at least 30,000/mcL Resume REVLIMID at next lower dose, continuously for Days 1-28 of repeated 28-day cycle If at the 5 mg daily dose, For a subsequent drop below 30,000/mcL Interrupt REVLIMID treatment. Do not dose below 5 mg daily for Day 1 to 21 of 28 day cycle Return to at least 30,000/mcL Resume REVLIMID at 5 mg daily for Days 1 to 21 of 28-day cycle.

Do not dose below 5 mg daily for Day 1 to 21 of 28 day cycle Absolute Neutrophil counts (ANC) Neutropenia in MM When Neutrophils Recommended Course Fall below 500/mcL Interrupt REVLIMID treatment, follow CBC weekly Return to at least 500/mcL Resume REVLIMID at next lower dose, continuously for Days 1-28 of repeated 28-day cycle If at 5 mg daily dose, For a subsequent drop below 500/mcL Interrupt REVLIMID treatment. Do not dose below 5 mg daily for Days 1 to 21 of 28-day cycle Return to at least 500/mcL Resume REVLIMID at 5 mg daily for Days 1 to 21 of 28-day cycle.

Do not dose below 5 mg daily for Days 1 to 21 of 28-day cycle

2.2 Recommended Dosage for Myelodysplastic Syndromes

2.2 Recommended Dosage for Myelodysplastic Syndromes The recommended starting dose of REVLIMID is 10 mg daily. Treatment is continued or modified based upon clinical and laboratory findings. Continue treatment until disease progression or unacceptable toxicity. Dose Adjustments for Hematologic Toxicities During MDS Treatment Patients who are dosed initially at 10 mg and who experience thrombocytopenia should have their dosage adjusted as follows: Platelet counts If thrombocytopenia develops WITHIN 4 weeks of starting treatment at 10 mg daily in MDS If baseline is at least 100,000/mcL When Platelets Recommended Course Fall below 50,000/mcL Interrupt REVLIMID treatment Return to at least 50,000/mcL Resume REVLIMID at 5 mg daily If baseline is below 100,000/mcL When Platelets Recommended Course Fall to 50% of the baseline value Interrupt REVLIMID treatment If baseline is at least 60,000/mcL and returns to at least 50,000/mcL Resume REVLIMID at 5 mg daily If baseline is below 60,000/mcL and returns to at least 30,000/mcL Resume REVLIMID at 5 mg daily If thrombocytopenia develops AFTER 4 weeks of starting treatment at 10 mg daily in MDS When Platelets Recommended Course Fall below 30,000/mcL or below 50,000/mcL with platelet transfusions Interrupt REVLIMID treatment Return to at least 30,000/mcL (without hemostatic failure) Resume REVLIMID at 5 mg daily Patients who experience thrombocytopenia at 5 mg daily should have their dosage adjusted as follows: If thrombocytopenia develops during treatment at 5 mg daily in MDS When Platelets Recommended Course Fall below 30,000/mcL or below 50,000/mcL with platelet transfusions Interrupt REVLIMID treatment Return to at least 30,000/mcL (without hemostatic failure) Resume REVLIMID at 2.5 mg daily Patients who are dosed initially at 10 mg and experience neutropenia should have their dosage adjusted as follows: Absolute Neutrophil counts (ANC) If neutropenia develops WITHIN 4 weeks of starting treatment at 10 mg daily in MDS If baseline ANC is at least 1,000/mcL When Neutrophils Recommended Course Fall below 750/mcL Interrupt REVLIMID treatment Return to at least 1,000/mcL Resume REVLIMID at 5 mg daily If baseline ANC is below 1,000/mcL When Neutrophils Recommended Course Fall below 500/mcL Interrupt REVLIMID treatment Return to at least 500/mcL Resume REVLIMID at 5 mg daily If neutropenia develops AFTER 4 weeks of starting treatment at 10 mg daily in MDS When Neutrophils Recommended Course Fall below 500/mcL for at least 7 days or below 500/mcL associated with fever (at least 38.5°C) Interrupt REVLIMID treatment Return to at least 500/mcL Resume REVLIMID at 5 mg daily Patients who experience neutropenia at 5 mg daily should have their dosage adjusted as follows: If neutropenia develops during treatment at 5 mg daily in MDS When Neutrophils Recommended Course Fall below 500/mcL for at least 7 days or below 500/mcL associated with fever (at least 38.5°C) Interrupt REVLIMID treatment Return to at least 500/mcL Resume REVLIMID at 2.5 mg daily

2.3 Recommended Dosage for Mantle Cell Lymphoma

2.3 Recommended Dosage for Mantle Cell Lymphoma The recommended starting dose of REVLIMID is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma. Treatment should be continued until disease progression or unacceptable toxicity. Treatment is continued, modified or discontinued based upon clinical and laboratory findings.

Dose Adjustments for Hematologic Toxicities During MCL Treatment Dose modification guidelines as summarized below are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicities considered to be related to REVLIMID. Platelet counts Thrombocytopenia during treatment in MCL When Platelets Recommended Course Fall below 50,000/mcL Interrupt REVLIMID treatment and follow CBC weekly Return to at least 50,000/mcL Resume REVLIMID at 5 mg less than the previous dose.

Do not dose below 5 mg daily Absolute Neutrophil counts (ANC) Neutropenia during treatment in MCL When Neutrophils Recommended Course Fall below 1,000/mcL for at least 7 days OR Falls below 1,000/mcL with an associated temperature at least 38.5°C OR Falls below 500/mcL Interrupt REVLIMID treatment and follow CBC weekly Return to at least 1,000/mcL Resume REVLIMID at 5 mg less than the previous dose. Do not dose below 5 mg daily

2.4 Recommended Dosage for Follicular Lymphoma or Marginal Zone

2.4 Recommended Dosage for Follicular Lymphoma or Marginal Zone Lymphoma The recommended starting dose of REVLIMID is 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles of treatment in combination with a rituximab-product. Refer to Section 14.4 for specific rituximab dosing from the AUGMENT trial.

For dose adjustments due to toxicity with rituximab, refer to the product prescribing information. Dose Adjustments for Hematologic Toxicities during FL or MZL Treatment Dose modification guidelines, as summarized below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to REVLIMID.

Platelet counts Thrombocytopenia during treatment in FL or MZL When Platelets Recommended Course Fall below 50,000/mcL Interrupt REVLIMID treatment and follow CBC weekly. Return to at least 50,000/mcL If patient starting dose was 20 mg daily, resume REVLIMID at 5 mg less than the previous dose. Do not dose below 5 mg daily.

If patient starting dose was 10 mg daily, resume at 5 mg less than previous dose. Do not dose below 2.5 mg daily. Absolute Neutrophil counts (ANC) Neutropenia during treatment in FL or MZL When Neutrophils Recommended Course Fall below 1,000/mcL for at least 7 days OR Falls below 1,000/mcL with an associated temperature at least 38.5°C OR Falls below 500/mcL Interrupt REVLIMID treatment and follow CBC weekly.

Return to at least 1,000/mcL If patient starting dose was 20 mg daily, resume REVLIMID at 5 mg less than the previous dose. Do not dose below 5 mg daily. If patient starting dose was 10 mg daily, resume at 5 mg less than previous dose. Do not dose below 2.5 mg daily.

2.5 Dosage Modifications for Non-Hematologic Adverse Reactions

2.5 Dosage Modifications for Non-Hematologic Adverse Reactions For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician's discretion at next lower dose level when toxicity has resolved to Grade 2 or below. Permanently discontinue REVLIMID for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reactions [see Warnings and Precautions (5.9, 5.15)].

2.6 Recommended Dosage for Patients with Renal Impairment

2.6 Recommended Dosage for Patients with Renal Impairment The recommendations for dosing patients with renal impairment are shown in the following table [see Clinical Pharmacology (12.3)]. Table 3: Dose Adjustments for Patients with Renal Impairment Renal Function (Cockcroft-Gault) Dose in REVLIMID Combination Therapy for MM and MCL Dose in REVLIMID Combination Therapy for FL and MZL Dose in REVLIMID Maintenance Therapy Following Auto-HSCT for MM and for MDS CLcr 30 to 60 mL/min 10 mg once daily 10 mg once daily 5 mg once daily CLcr below 30 mL/min (not requiring dialysis) 15 mg every other day 5 mg once daily 2.5 mg once daily CLcr below 30 mL/min (requiring dialysis) 5 mg once daily.

On dialysis days, administer the dose following dialysis. 5 mg once daily. On dialysis days, administer the dose following dialysis. 2.5 mg once daily. On dialysis days, administer the dose following dialysis. REVLIMID Combination Therapy for MM: For CLcr of 30 to 60 mL/min, consider escalating the dose to 15 mg after 2 cycles if the patient tolerates the 10 mg dose of lenalidomide without dose-limiting toxicity.

REVLIMID Maintenance Therapy Following Auto-HSCT for MM and for MCL and MDS: Base subsequent REVLIMID dose increase or decrease on individual patient treatment tolerance [see Dosage and Administration (2.1 - 2.3)]. REVLIMID Combination Therapy for FL or for MZL: For patients with CLcr of 30 to 60 mL/min, after 2 cycles, the REVLIMID dose may be increased to 15 mg orally if the patient has tolerated therapy.

2.7 Administration

2.7 Administration Advise patients to take REVLIMID orally at about the same time each day, either with or without food. Advise patients to swallow REVLIMID capsules whole with water and not to open, break, or chew them.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations, pharmacokinetics)

2.6 Recommended Dosage for Patients with Renal Impairment The recommendations for dosing patients with renal impairment are shown in the following table [see Clinical Pharmacology (12.3)]. Table 3: Dose Adjustments for Patients with Renal Impairment Renal Function (Cockcroft-Gault) Dose in REVLIMID Combination Therapy for MM and MCL Dose in REVLIMID Combination Therapy for FL and MZL Dose in REVLIMID Maintenance Therapy Following Auto-HSCT for MM and for MDS CLcr 30 to 60 mL/min 10 mg once daily 10 mg once daily 5 mg once daily CLcr below 30 mL/min (not requiring dialysis) 15 mg every other day 5 mg once daily 2.5 mg once daily CLcr below 30 mL/min (requiring dialysis) 5 mg once daily.

On dialysis days, administer the dose following dialysis. 5 mg once daily. On dialysis days, administer the dose following dialysis. 2.5 mg once daily. On dialysis days, administer the dose following dialysis. REVLIMID Combination Therapy for MM: For CLcr of 30 to 60 mL/min, consider escalating the dose to 15 mg after 2 cycles if the patient tolerates the 10 mg dose of lenalidomide without dose-limiting toxicity.

REVLIMID Maintenance Therapy Following Auto-HSCT for MM and for MCL and MDS: Base subsequent REVLIMID dose increase or decrease on individual patient treatment tolerance [see Dosage and Administration (2.1 - 2.3)]. REVLIMID Combination Therapy for FL or for MZL: For patients with CLcr of 30 to 60 mL/min, after 2 cycles, the REVLIMID dose may be increased to 15 mg orally if the patient has tolerated therapy.

8.6 Renal Impairment Adjust the starting dose of REVLIMID based on the creatinine clearance value and for patients on dialysis [see Dosage and Administration (2.6)].

Renal Impairment: Eight subjects with mild renal impairment (creatinine clearance (CLcr) 50 to 79 mL/min calculated using Cockcroft-Gault), 9 subjects with moderate renal impairment (CLcr 30 to 49 mL/min), 4 subjects with severe renal impairment (CLcr < 30 mL/min), and 6 patients with end stage renal disease (ESRD) requiring dialysis were administered a single 25 mg dose of REVLIMID. Three healthy subjects of similar age with normal renal function (CLcr > 80 mL/min) were also administered a single 25 mg dose of REVLIMID.

As CLcr decreased, half-life increased and drug clearance decreased linearly.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness have not been established in pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use MM In Combination: Overall, of the 1613 patients in the NDMM study who received study treatment, 94% (1521 /1613) were 65 years of age or older, while 35% (561/1613) were over 75 years of age. The percentage of patients over age 75 was similar between study arms (Rd Continuous: 33%; Rd18: 34%; MPT: 33%).

Overall, across all treatment arms, the frequency in most of the adverse reaction categories (eg, all adverse reactions, grade 3/4 adverse reactions, serious adverse reactions) was higher in older (> 75 years of age) than in younger (≤ 75 years of age) subjects. Grade 3 or 4 adverse reactions in the General Disorders and Administration Site Conditions body system were consistently reported at a higher frequency (with a difference of at least 5%) in older subjects than in younger subjects across all treatment arms.

Grade 3 or 4 adverse reactions in the Infections and Infestations, Cardiac Disorders (including cardiac failure and congestive cardiac failure), Skin and Subcutaneous Tissue Disorders, and Renal and Urinary Disorders (including renal failure) body systems were also reported slightly, but consistently, more frequently (<5% difference), in older subjects than in younger subjects across all treatment arms. For other body systems (e.g., Blood and Lymphatic System Disorders, Infections and Infestations, Cardiac Disorders, Vascular Disorders), there was a less consistent trend for increased frequency of grade 3/4 adverse reactions in older vs younger subjects across all treatment arms Serious adverse reactions were generally reported at a higher frequency in the older subjects than in the younger subjects across all treatment arms.

MM Maintenance Therapy: Overall, 10% (106/1018) of patients were 65 years of age or older, while no patients were over 75 years of age. Grade 3 or 4 adverse reactions were higher in the REVLIMID arm (more than 5% higher) in the patients 65 years of age or older versus younger patients. The frequency of Grade 3 or 4 adverse reactions in the Blood and Lymphatic System Disorders were higher in the REVLIMID arm (more than 5% higher) in the patients 65 years of age or older versus younger patients.

There were not a sufficient number of patients 65 years of age or older in REVLIMID maintenance studies who experienced either a serious adverse reaction, or discontinued therapy due to an adverse reaction to determine whether elderly patients respond relative to safety differently from younger patients. MM After At Least One Prior Therapy: Of the 703 MM patients who received study treatment in Studies 1 and 2, 45% were age 65 or over while 12% of patients were age 75 and over.

The percentage of patients age 65 or over was not significantly different between the REVLIMID/dexamethasone and placebo/dexamethasone groups. Of the 353 patients who received REVLIMID/dexamethasone, 46% were age 65 and over. In both studies, patients > 65 years of age were more likely than patients ≤ 65 years of age to experience DVT, pulmonary embolism, atrial fibrillation, and renal failure following use of REVLIMID.

No differences in efficacy were observed between patients over 65 years of age and younger patients. Of the 148 patients with del 5q MDS enrolled in the major study, 38% were age 65 and over, while 33% were age 75 and over. Although the overall frequency of adverse reactions (100%) was the same in patients over 65 years of age as in younger patients, the frequency of serious adverse reactions was higher in patients over 65 years of age than in younger patients (54% vs. 33%).

A greater proportion of patients over 65 years of age discontinued from the clinical studies because of adverse reactions than the proportion of younger patients (27% vs. 16%). No differences in efficacy were observed between patients over 65 years of age and younger patients. Of the 134 patients with MCL enrolled in the MCL trial, 63% were age 65 and over, while 22% of patients were age 75 and over.

The overall frequency of adverse reactions was similar in patients over 65 years of age and in younger patients (98% vs. 100%). The overall incidence of grade 3 and 4 adverse reactions was also similar in these 2 patient groups (79% vs. 78%, respectively). The frequency of serious adverse reactions was higher in patients over 65 years of age than in younger patients (55% vs. 41%).

No differences in efficacy were observed between patients over 65 years of age and younger patients. FL or MZL in Combination: Overall, 48% (282/590) of patients were 65 years of age or older, while 14% (82/590) of patients were over 75 years of age. The overall frequency of adverse reactions was similar in patients 65 years of age or older and younger patients for both studies pooled (98%).

Grade 3 or 4 adverse reactions were higher in the REVLIMID arm (more than 5% higher) in the patients 65 years of age or older versus younger patients (71% versus 59%). The frequency of Grade 3 or 4 adverse reactions were higher in the REVLIMID arm (more than 5% higher) in the patients 65 years of age or older versus younger patients in the Blood and Lymphatic System Disorders (47% versus 40%) and Infections and Infestations (16% versus 11%).

Serious adverse reactions were higher in the REVLIMID arm (more than 5% higher) in the patients 65 years of age or older versus younger patients (37% versus 18%). The frequency of serious adverse reactions were higher in the REVLIMID arm (more than 5% higher) in the patients 65 years of age or older versus younger patients in Infections and Infestations (15% versus 6%).

Since elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitor renal function.

Administration

2.7 Administration Advise patients to take REVLIMID orally at about the same time each day, either with or without food. Advise patients to swallow REVLIMID capsules whole with water and not to open, break, or chew them.

US FDA label

Dosage forms

Philippines

  • Capsule: 5 mg, 10 mg, 15 mg, 25 mg

Registered products in the Philippines

18 products registered with the Food and Drug Administration (FDA) Philippines list Lenalidomide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products18
Philippine FDA-registered products for Lenalidomide
Package insert
LenagenLenalidomide
10 mg CapsuleAlu/Clear PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Metro Drug, Inc.
DR-XY47661
Jan 11, 2027
LenagenLenalidomide
15 mg CapsuleAlu/Clear PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Metro Drug, Inc.
DR-XY47660
Jan 11, 2027
LenagenLenalidomide
25 mg CapsuleAlu/Clear PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Metro Drug, Inc.
DR-XY47659
Jan 11, 2027
LenagenLenalidomide
5 mg CapsuleAlu/Clear PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Metro Drug, Inc.
DR-XY47662
Jan 11, 2027
Lenalid 10Lenalidomide
10 mg CapsuleClear PVC/Aclar/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Natco Pharma Limited Pharma Division (Unit IV and V)India
Natco Lifesciences Philippines, Inc.
DR-XY48668
Mar 27, 2028
Lenalid 10Lenalidomide
10 mg CapsuleHDPE Bottle x 28's (Box of 1 bottle x 28 capsules)
RxVAT-exempt
Natco Pharma Limited (Unit IV and V)India
Natco Lifesciences Philippines, Inc.
DR-XY48670
Mar 28, 2027
Lenalid 15Lenalidomide
15 mg CapsuleClear PVC/Aclar/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Natco Pharma Limited Pharma Division (Unit IV and V)India
Natco Lifesciences Philippines, Inc.
DR-XY48667
Mar 27, 2028
Lenalid 25Lenalidomide
25 mg CapsuleClear PVC/Aclar/Alu Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Natco Pharma Limited Pharma Division (Unit IV and V)India
Natco Lifesciences Philippines, Inc.
DR-XY48666
Mar 27, 2028
Lenalid 5Lenalidomide
5 mg CapsuleClear PVC/Aclar/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Natco Pharma Limited Pharma Division (Unit IV and V)India
Natco Lifesciences Philippines, Inc.
DR-XY48669
Mar 27, 2028
Lenalid 5Lenalidomide
5 mg CapsuleHDPE Bottle x 28's (Box of 1 bottle x 28 capsules)
RxVAT-exempt
Natco Pharma Limited (Unit IV and V)India
Natco Lifesciences Philippines, Inc.
DR-XY48671
Mar 28, 2027
Lenoma 10Lenalidomide
10 mg CapsuleOPA/Alu/PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Nano Fanavaran Darouei Alvand (Nanoalvand)Iran
SRS Life Sciences Inc.
DR-XY49499
Sep 9, 2030
Lenoma 25Lenalidomide
25 mg CapsuleOPA/Alu/PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Nano Fanavaran Darouei Alvand (Nanoalvand)Iran
SRS Life Sciences Inc.
DR-XY49498
Sep 9, 2030
Lenoma 5Lenalidomide
5 mg CapsuleOPA/Alu/PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Nano Fanavaran Darouei Alvand (Nanoalvand)Iran
SRS Life Sciences Inc.
DR-XY49500
Sep 9, 2030
Lenzest 10Lenalidomide
10 mg CapsuleAlu clear PVC blister pack x 7 (Box of 21's)
RxVAT-exempt
Sun Pharmaceuticals Industries Ltd.India
Sun Pharma Philippines, Inc.
DR-XY48493
Nov 25, 2027
Lenzest 25Lenalidomide
25 mg CapsuleAlu/Clear PVC Blister Pack x 7's (Box of 21's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DR-XY48492
Nov 25, 2027
Linalix 10Lenalidomide
10 mg CapsuleHDPE bottle x 30's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DR-XY49296
Jan 3, 2030
Linalix 15Lenalidomide.
15 mg CapsuleHDPE bottle pack
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DR-XY49295
Jan 3, 2030
Linalix 5Lenalidomide
5 mg CapsuleHDPE bottle x 30's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DR-XY49297
Jan 3, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Capsules:

  • 2.5 mg, white and blue-green opaque hard capsules imprinted "REV" on one half and "2.5 mg" on the other half in black ink
  • 5 mg, white opaque capsules imprinted "REV" on one half and "5 mg" on the other half in black ink
  • 10 mg, blue/green and pale yellow opaque capsules imprinted "REV" on one half and "10 mg" on the other half in black ink
  • 15 mg, powder blue and white opaque capsules imprinted "REV" on one half and "15 mg" on the other half in black ink
  • 20 mg, powder blue and blue-green opaque hard capsules imprinted "REV" on one half and "20 mg" on the other half in black ink
  • 25 mg, white opaque capsules imprinted "REV" on one half and "25 mg" on the other half in black ink Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg (3).

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

  • Increased Mortality: serious and fatal cardiac adverse reactions occurred in patients with CLL treated with REVLIMID (5.5).
  • Second Primary Malignancies (SPM): Higher incidences of SPM were observed in controlled trials of patients with MM receiving REVLIMID (5.6).
  • Increased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue (5.7).
  • Hepatotoxicity: Hepatic failure including fatalities; monitor liver function. Stop REVLIMID and evaluate if hepatotoxicity is suspected (5.8).
  • Severe Cutaneous Reactions: Discontinue REVLIMID for severe reactions (5.9).
  • Tumor lysis syndrome (TLS) including fatalities: Monitor patients at risk of TLS (i.e., those with high tumor burden) and take appropriate precautions (5.10).
  • Tumor flare reaction: Serious tumor flare reactions, including fatal reactions, have occurred during investigational use of REVLIMID for chronic lymphocytic leukemia and lymphoma (5.11).
  • Impaired Stem Cell mobilization: A decrease in the number of CD34+ cells collected after treatment (> 4 cycles) with REVLIMID has been reported. Consider early referral to transplant center (5.12).
  • Early mortality in MCL: Higher rate of early deaths have occurred in patients with MCL (5.14).
  • Hypersensitivity: Monitor patients for potential hypersensitivity. Discontinue REVLIMID for angioedema and …
5.1 Embryo-Fetal Toxicity

5.1 Embryo-Fetal Toxicity REVLIMID is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes life-threatening human birth defects or embryo-fetal death [see Use in Specific Populations (8.1)]. An embryo-fetal development study in monkeys indicates that lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy, similar to birth defects observed in humans following exposure to thalidomide during pregnancy.

REVLIMID is only available through the Lenalidomide REMS program [see Warnings and Precautions (5.2)]. Females of Reproductive Potential Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning REVLIMID therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy.

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, beginning 4 weeks prior to initiating treatment with REVLIMID, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of REVLIMID therapy. Two negative pregnancy tests must be obtained prior to initiating therapy.

The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing REVLIMID therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles or every 2 weeks in females with irregular menstrual cycles [see Use in Specific Populations (8.3)]. Males Lenalidomide is present in the semen of patients receiving the drug.

Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 4 weeks after discontinuing REVLIMID, even if they have undergone a successful vasectomy. Male patients taking REVLIMID must not donate sperm and for up to 4 weeks after discontinuing REVLIMID [see Use in Specific Populations (8.3)].

Blood Donation Patients must not donate blood during treatment with REVLIMID and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to REVLIMID.

5.2 Lenalidomide REMS Program

5.2 Lenalidomide REMS Program Because of the embryo-fetal risk [see Warnings and Precautions (5.1)], REVLIMID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), the Lenalidomide REMS program. Required components of the Lenalidomide REMS program include the following:

  • Prescribers must be certified with the Lenalidomide REMS program by enrolling and complying with the REMS requirements.
  • Patients must sign a Patient-Physician agreement form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see Use in Specific Populations (8.3)] and males must comply with contraception requirements [see Use in Specific Populations (8.3)].
  • Pharmacies must be certified with the Lenalidomide REMS program, must only dispense to patients who are authorized to receive REVLIMID and comply with REMS requirements. Further information about the Lenalidomide REMS program is available at www.lenalidomiderems.com or by telephone at 1-888-423-5436.
5.3 Hematologic Toxicity

5.3 Hematologic Toxicity REVLIMID can cause significant neutropenia and thrombocytopenia. Monitor patients with neutropenia for signs of infection. Advise patients to observe for bleeding or bruising, especially with use of concomitant medication that may increase risk of bleeding. Patients taking REVLIMID should have their complete blood counts assessed periodically as described below [see Dosage and Administration (2.1, 2.2, 2.3)].

Monitor complete blood counts (CBC) in patients taking REVLIMID in combination with dexamethasone or as REVLIMID maintenance therapy for MM every 7 days (weekly) for the first 2 cycles, on Days 1 and 15 of Cycle 3, and every 28 days (4 weeks) thereafter. A dose interruption and/or dose reduction may be required [see Dosage and Administration (2.1)].

In the MM maintenance therapy trials, Grade 3 or 4 neutropenia was reported in up to 59% of REVLIMID-treated patients and Grade 3 or 4 thrombocytopenia in up to 38% of REVLIMID-treated patients [see Adverse Reactions (6.1)]. Monitor complete blood counts (CBC) in patients taking REVLIMID for MDS weekly for the first 8 weeks and at least monthly thereafter.

Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the MDS study. In the 48% of patients who developed Grade 3 or 4 neutropenia, the median time to onset was 42 days (range, 14-411 days), and the median time to documented recovery was 17 days (range, 2-170 days). In the 54% of patients who developed Grade 3 or 4 thrombocytopenia, the median time to onset was 28 days (range, 8-290 days), and the median time to documented recovery was 22 days (range, 5-224 days) [see Boxed Warning and Dosage and Administration (2.2)].

Monitor complete blood counts (CBC) in patients taking REVLIMID for MCL weekly for the first cycle (28 days), every 2 weeks during cycles 2-4, and then monthly thereafter. Patients may require dose interruption and/or dose reduction. In the MCL trial, Grade 3 or 4 neutropenia was reported in 43% of the patients. Grade 3 or 4 thrombocytopenia was reported in 28% of the patients.

Monitor complete blood counts (CBC) in patients taking REVLIMID for FL or MZL weekly for the first 3 weeks of Cycle 1 (28 days), every 2 weeks during Cycles 2-4, and then monthly thereafter. Patients may require dose interruption and/or dose reduction. In the AUGMENT and MAGNIFY trials, Grade 3 or 4 neutropenia was reported in 50% and 33%, respectively, of patients in the REVLIMID/rituximab arm.

Grade 3 or 4 thrombocytopenia was reported in 2% and 8%, respectively, of patients in the REVLIMID/rituximab arm [see Adverse Reactions (6.1)].

5.4 Venous and Arterial Thromboembolism

5.4 Venous and Arterial Thromboembolism Venous thromboembolic events (VTE [DVT and PE]) and arterial thromboembolic events (ATE, myocardial infarction and stroke) are increased in patients treated with REVLIMID. A significantly increased risk of DVT (7.4%) and of PE (3.7%) occurred in patients with MM after at least one prior therapy who were treated with REVLIMID and dexamethasone therapy compared to patients treated in the placebo and dexamethasone group (3.1% and 0.9%) in clinical trials with varying use of anticoagulant therapies.

In the newly diagnosed multiple myeloma (NDMM) study in which nearly all patients received antithrombotic prophylaxis, DVT was reported as a serious adverse reaction (3.6%, 2.0%, and 1.7%) in the Rd Continuous, Rd18, and MPT Arms, respectively. The frequency of serious adverse reactions of PE was similar between the Rd Continuous, Rd18, and MPT Arms (3.8%, 2.8%, and 3.7%, respectively) [see Boxed Warning and Adverse Reactions (6.1)].

Myocardial infarction (1.7%) and stroke (CVA) (2.3%) are increased in patients with MM after at least one prior therapy who were treated with REVLIMID and dexamethasone therapy compared to patients treated with placebo and dexamethasone (0.6%, and 0.9%) in clinical trials. In the NDMM study, myocardial infarction (including acute) was reported as a serious adverse reaction (2.3%, 0.6%, and 1.1%) in the Rd Continuous, Rd18, and MPT Arms, respectively.

The frequency of serious adverse reactions of CVA was similar between the Rd Continuous, Rd18, and MPT Arms (0.8%, 0.6 %, and 0.6%, respectively) [see Adverse Reactions (6.1)]. Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking).

In controlled clinical trials that did not use concomitant thromboprophylaxis, 21.5% overall thrombotic events (Standardized MedDRA Query Embolic and Thrombotic events) occurred in patients with refractory and relapsed MM who were treated with REVLIMID and dexamethasone compared to 8.3% thrombosis in patients treated with placebo and dexamethasone. The median time to first thrombosis event was 2.8 months.

In the NDMM study in which nearly all patients received antithrombotic prophylaxis, the overall frequency of thrombotic events was 17.4% in patients in the combined Rd Continuous and Rd18 Arms, and was 11.6% in the MPT Arm. The median time to first thrombosis event was 4.3 months in the combined Rd Continuous and Rd18 Arms.

In the AUGMENT trial, the incidence of VTE (including DVT and PE) in FL or MZL patients was 3.4% in the REVLIMID/rituximab arm [see Adverse Reactions (6.1)]. In the AUGMENT trial, the incidence of ATE (including MI) in FL or MZL patients was 0.6% in the REVLIMID/rituximab arm [see Adverse Reactions (6.1)]. Thromboprophylaxis is recommended.

The regimen of thromboprophylaxis should be based on an assessment of the patient's underlying risks. Instruct patients to report immediately any signs and symptoms suggestive of thrombotic events. ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision in patients receiving REVLIMID [see Drug Interactions (7.2)].

5.5 Increased Mortality in Patients with CLL

5.5 Increased Mortality in Patients with CLL In a prospective randomized (1:1) clinical trial in the first line treatment of patients with chronic lymphocytic leukemia, single agent REVLIMID therapy increased the risk of death as compared to single agent chlorambucil. In an interim analysis, there were 34 deaths among 210 patients on the REVLIMID treatment arm compared to 18 deaths among 211 patients in the chlorambucil treatment arm, and hazard ratio for overall survival was 1.92 [95% CI: 1.08 – 3.41], consistent with a 92% increase in the risk of death.

The trial was halted for safety in July 2013. Serious adverse cardiovascular reactions, including atrial fibrillation, myocardial infarction, and cardiac failure occurred more frequently in the REVLIMID treatment arm. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials.

5.6 Second Primary Malignancies

5.6 Second Primary Malignancies In clinical trials in patients with MM receiving REVLIMID, an increase of hematologic plus solid tumor second primary malignancies (SPM) notably AML and MDS have been observed. An increase in hematologic SPM including AML and MDS occurred in 5.3% of patients with NDMM receiving REVLIMID in combination with oral melphalan compared with 1.3% of patients receiving melphalan without REVLIMID.

The frequency of AML and MDS cases in patients with NDMM treated with REVLIMID in combination with dexamethasone without melphalan was 0.4%. In patients receiving REVLIMID maintenance therapy following high dose intravenous melphalan and auto-HSCT, hematologic SPM occurred in 7.5% of patients compared to 3.3% in patients receiving placebo.

The incidence of hematologic plus solid tumor (excluding squamous cell carcinoma and basal cell carcinoma) SPM was 14.9%, compared to 8.8% in patients receiving placebo with a median follow-up of 91.5 months. Non-melanoma skin cancer SPM, including squamous cell carcinoma and basal cell carcinoma, occurred in 3.9% of patients receiving REVLIMID maintenance, compared to 2.6% in the placebo arm.

In patients with relapsed or refractory MM treated with REVLIMID/dexamethasone, the incidence of hematologic plus solid tumor (excluding squamous cell carcinoma and basal cell carcinoma) SPM was 2.3% versus 0.6% in the dexamethasone alone arm. Non-melanoma skin cancer SPM, including squamous cell carcinoma and basal cell carcinoma, occurred in 3.1% of patients receiving REVLIMID/dexamethasone, compared to 0.6% in the dexamethasone alone arm.

Patients who received REVLIMID-containing therapy until disease progression did not show a higher incidence of invasive SPM than patients treated in the fixed duration REVLIMID-containing arms. Monitor patients for the development of second primary malignancies. Take into account both the potential benefit of REVLIMID and the risk of second primary malignancies when considering treatment with REVLIMID.

In the AUGMENT trial with FL or MZL patients receiving REVLIMID/rituximab therapy, hematologic plus solid tumor SPMs, notably AML, have been observed. In the AUGMENT trial, hematologic SPM of AML occurred in 0.6% of patients with FL or MZL receiving REVLIMID/rituximab therapy. The incidence of hematologic plus solid tumor SPMs (excluding nonmelanoma skin cancers) was 1.7% in the REVLIMID/rituximab arm with a median follow-up of 29.8 months (range 0.5 to 51.3 months) [see Adverse Reactions (6.1)].

Monitor patients for the development of second primary malignancies. Take into account both the potential benefit of REVLIMID and the risk of second primary malignancies when considering treatment with REVLIMID.

5.7 Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide

5.7 Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone In two randomized clinical trials in patients with MM, the addition of pembrolizumab to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

5.8 Hepatotoxicity

5.8 Hepatotoxicity Hepatic failure, including fatal cases, has occurred in patients treated with REVLIMID in combination with dexamethasone. In clinical trials, 15% of patients experienced hepatotoxicity (with hepatocellular, cholestatic and mixed characteristics); 2% of patients with MM and 1% of patients with myelodysplasia had serious hepatotoxicity events.

The mechanism of drug-induced hepatotoxicity is unknown. Pre-existing viral liver disease, elevated baseline liver enzymes, and concomitant medications may be risk factors. Monitor liver enzymes periodically. Stop REVLIMID upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered.

5.9 Severe Cutaneous Reactions

5.9 Severe Cutaneous Reactions Severe cutaneous reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis.

These events can be fatal. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID. Consider REVLIMID interruption or discontinuation for Grade 2-3 skin rash. Permanently discontinue REVLIMID for Grade 4 rash, exfoliative or bullous rash, or for other severe cutaneous reactions such as SJS, TEN or DRESS [see Dosage and Administration (2.5)].

5.10 Tumor Lysis Syndrome

5.10 Tumor Lysis Syndrome Fatal instances of tumor lysis syndrome (TLS) have been reported during treatment with REVLIMID. The patients at risk of TLS are those with high tumor burden prior to treatment. Monitor patients at risk closely and take appropriate preventive approaches. In the AUGMENT trial in FL or MZL patients, TLS occurred in 2 patients (1.1%) in the REVLIMID/rituximab arm.

TLS occurred in 1 patient (0.5%) in the MAGNIFY trial during the REVLIMID/rituximab induction period; the event was a serious, Grade 3 adverse reaction.

5.11 Tumor Flare Reaction

5.11 Tumor Flare Reaction Tumor flare reaction (TFR), including fatal reactions, have occurred during investigational use of REVLIMID for CLL and lymphoma, and is characterized by tender lymph node swelling, low grade fever, pain and rash. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials.

Monitoring and evaluation for TFR is recommended in patients with MCL, FL, or MZL. Tumor flare reaction may mimic progression of disease (PD). In the MCL trial, 13/134 (10%) of subjects experienced TFR; all reports were Grade 1 or 2 in severity. All of the events occurred in Cycle 1 and one patient developed TFR again in Cycle 11.

In the AUGMENT trial in FL or MZL patients, TFR was reported in 19/176 (10.8%) of patients in REVLIMID with rituximab arm; one patient in the REVLIMID/rituximab arm experienced a Grade 3 TFR. In the MAGNIFY trial, 9/222 (4.1%) of patients experienced TFR; all reports were Grade 1 or 2 in severity and 1 event was considered as serious.

In a separate MCL phase 2 trial, one case of TFR resulted in a fatal outcome. REVLIMID may be continued in patients with Grade 1 and 2 TFR without interruption or modification, at the physician's discretion. Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms.

In patients with Grade 3 or 4 TFR, it is recommended to withhold treatment with REVLIMID until TFR resolves to ≤ Grade 1. Patients with Grade 3 or 4 TFR may be treated for management of symptoms per the guidance for treatment of Grade 1 and 2 TFR.

5.12 Impaired Stem Cell Mobilization

5.12 Impaired Stem Cell Mobilization A decrease in the number of CD34+ cells collected after treatment (> 4 cycles) with REVLIMID has been reported. In patients who are auto-HSCT candidates, referral to a transplant center should occur early in treatment to optimize the timing of the stem cell collection. In patients who received more than 4 cycles of a REVLIMID-containing treatment or for whom inadequate numbers of CD 34+ cells have been collected with G-CSF alone, G-CSF with cyclophosphamide or the combination of G-CSF with a CXCR4 inhibitor may be considered.

5.13 Thyroid Disorders

5.13 Thyroid Disorders Both hypothyroidism and hyperthyroidism have been reported [see Adverse Reactions (6.2)]. Measure thyroid function before start of REVLIMID treatment and during therapy.

5.14 Early Mortality in Patients with MCL

5.14 Early Mortality in Patients with MCL In another MCL study, there was an increase in early deaths (within 20 weeks), 12.9% in the REVLIMID arm versus 7.1% in the control arm. On exploratory multivariate analysis, risk factors for early deaths include high tumor burden, MIPI score at diagnosis, and high WBC at baseline (≥ 10 x 10 9 /L).

5.15 Hypersensitivity

5.15 Hypersensitivity Hypersensitivity, including angioedema, anaphylaxis, and anaphylactic reactions to REVLIMID has been reported. Permanently discontinue REVLIMID for angioedema and anaphylaxis [see Dosage and Administration (2.2)].

Drug interactions

Drug interactions (US label) US FDA label

  • Digoxin: Monitor digoxin plasma levels periodically due to increased C max and AUC with concomitant REVLIMID therapy (7.1).
  • Concomitant use of erythropoietin stimulating agents or estrogen containing therapies with REVLIMID may increase the risk of thrombosis (7.2).
7.1 Digoxin

7.1 Digoxin When digoxin was co-administered with multiple doses of REVLIMID (10 mg/day) the digoxin C max and AUC inf were increased by 14%. Periodically monitor digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, during administration of REVLIMID.

7.2 Concomitant Therapies That May Increase the Risk of Thrombosis

7.2 Concomitant Therapies That May Increase the Risk of Thrombosis Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as estrogen containing therapies, should be used with caution after making a benefit-risk assessment in patients receiving REVLIMID [see Warnings and Precautions (5.4)].

7.3 Warfarin

7.3 Warfarin Co-administration of multiple doses of REVLIMID (10 mg/day) with a single dose of warfarin (25 mg) had no effect on the pharmacokinetics of lenalidomide or R- and S-warfarin. Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant REVLIMID administration.

It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Co-administration of REVLIMID (25 mg) after multiple doses of a P-gp inhibitor such as quinidine (600 mg twice daily) did not significantly increase the Cmax or AUC of lenalidomide.

Co-administration of the P-gp inhibitor and substrate temsirolimus (25 mg),with REVLIMID (25 mg) did not significantly alter the pharmacokinetics of lenalidomide, temsirolimus, or sirolimus (metabolite of temsirolimus).

In vitro studies demonstrated that REVLIMID is a substrate of P-glycoprotein (P-gp).

REVLIMID is not a substrate of human breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) transporters MRP1, MRP2, or MRP3, organic anion transporters (OAT) OAT1 and OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), organic cation transporters (OCT) OCT1 and OCT2, multidrug and toxin extrusion protein (MATE) MATE1, and organic cation transporters novel (OCTN) OCTN1 and OCTN2.

Lenalidomide is not an inhibitor of P-gp, bile salt export pump (BSEP), BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, or OCT2.

Lenalidomide does not inhibit or induce CYP450 isoenzymes.

Also, lenalidomide does not inhibit bilirubin glucuronidation formation in human liver microsomes with UGT1A1 genotyped as UGT1A1*1/*1, UGT1A1*1/*28, and UGT1A1*28/*28.

Adverse reactions

Adverse reactions (US label) US FDA label

The following clinically significant adverse reactions are described in detail in other sections of the prescribing information: o Embryo-Fetal Toxicity [see Boxed Warning, Warnings and Precautions (5.1, 5.2)] o Hematologic Toxicity [see Boxed Warning, Warnings and Precautions (5.3)] o Venous and Arterial Thromboembolism [see Boxed Warning, Warnings and Precautions (5.4)] o Increased Mortality in Patients with CLL [see Warnings and Precautions (5.5)] o Second Primary Malignancies [see Warnings and Precautions (5.6)] o Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone [see Warnings and Precautions (5.7)] o Hepatotoxicity [see Warnings and Precautions (5.8)] o Severe Cutaneous Reactions [see Warnings and Precautions (5.9)] o Tumor Lysis Syndrome [see Warnings and Precautions (5.10)] o Tumor Flare Reactions [see Warnings and Precautions (5.11)] o Impaired Stem Cell Mobilization [see Warnings and Precautions (5.12)] o Thyroid Disorders [see Warnings and Precautions (5.13)] o Early Mortality in Patients with MCL [see Warnings and Precautions (5.14)] o Hypersensitivity [see Warnings and Precautions (5.15)]

  • MM: Most common adverse reactions (≥20%) include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, …
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Newly Diagnosed MM – REVLIMID Combination Therapy: Data were evaluated from 1613 patients in a large phase 3 study who received at least one dose of REVLIMID with low dose dexamethasone (Rd) given for 2 different durations of time (i.e., until progressive disease [Arm Rd Continuous; N=532] or for up to eighteen 28-day cycles [72 weeks, Arm Rd18; N=540] or who received melphalan, prednisone and thalidomide (Arm MPT; N=541) for a maximum of twelve 42-day cycles (72 weeks).

The median treatment duration in the Rd Continuous arm was 80.2 weeks (range 0.7 to 246.7) or 18.4 months (range 0.16 to 56.7). In general, the most frequently reported adverse reactions were comparable in Arm Rd Continuous and Arm Rd18, and included diarrhea, anemia, constipation, peripheral edema, neutropenia, fatigue, back pain, nausea, asthenia, and insomnia.

The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphopenia, dyspnea, DVT, hyperglycemia, and leukopenia. The highest frequency of infections occurred in Arm Rd Continuous (75%) compared to Arm MPT (56%).

There were more grade 3 and 4 and serious adverse reactions of infection in Arm Rd Continuous than either Arm MPT or Rd18. In the Rd Continuous arm, the most common adverse reactions leading to dose interruption of REVLIMID were infection events (28.8%); overall, the median time to the first dose interruption of REVLIMID was 7 weeks.

The most common adverse reactions leading to dose reduction of REVLIMID in the Rd Continuous arm were hematologic events (10.7%); overall, the median time to the first dose reduction of REVLIMID was 16 weeks. In the Rd Continuous arm, the most common adverse reactions leading to discontinuation of REVLIMID were infection events (3.4%).

In both Rd arms, the frequencies of onset of adverse reactions were generally highest in the first 6 months of treatment and then the frequencies decreased over time or remained stable throughout treatment, except for cataracts. The frequency of onset of cataracts increased over time with 0.7% during the first 6 months and up to 9.6% by the 2nd year of treatment with Rd Continuous.

Table 4 summarizes the adverse reactions reported for the Rd Continuous, Rd18, and MPT treatment arms. Table 4: All Adverse Reactions in ≥5% and Grade 3/4 Adverse Reactions in ≥1% of Patients with MM in the Rd Continuous or Rd18 Arms* Note: A subject with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse Reaction. a All treatment-emergent adverse events in at least 5% of subjects in the Rd Continuous or Rd18 Arms and at least a 2% higher frequency (%) in either the Rd Continuous or Rd18 Arms compared to the MPT Arm. b All grade 3 or 4 treatment-emergent adverse events in at least 1% of subjects in the Rd Continuous or Rd18 Arms and at least a 1% higher frequency (%) in either the Rd Continuous or Rd18 Arms compared to the MPT Arm. c Serious treatment-emergent adverse events in at least 1% of subjects in the Rd Continuous or Rd18 Arms and at least a 1% higher frequency (%) in either the Rd Continuous or Rd18 Arms compared to the MPT Arm. d Preferred terms for the blood and lymphatic system disorders body system were included by medical judgment as known adverse reactions for Rd Continuous/Rd18, and have also been reported as serious. e Footnote “a” not applicable. f Footnote “b” not applicable. @ - adverse reactions in which at least one resulted in a fatal outcome. % - adverse reactions in which at least one was considered to be life threatening (if the outcome of the reaction was death, it is included with death cases). *Adverse reactions included in combined adverse reaction terms: Abdominal Pain: Abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain Pneumonias: Pneumonia, lobar pneumonia, pneumonia pneumococcal, bronchopneumonia, pneumocystis jiroveci pneumonia, pneumonia legionella, pneumonia staphylococcal, pneumonia klebsiella, atypical pneumonia, pneumonia bacterial, pneumonia escherichia, pneumonia streptococcal, pneumonia viral Sepsis: Sepsis, septic shock, urosepsis, escherichia sepsis, neutropenic sepsis, pneumococcal sepsis, staphylococcal sepsis, bacterial sepsis, meningococcal sepsis, enterococcal sepsis, klebsiella sepsis, pseudomonal sepsis Rash: Rash, rash pruritic, rash erythematous, rash maculo-papular, rash generalized, rash papular, exfoliative rash, rash follicular, rash macular, drug rash with eosinophilia and systemic symptoms, erythema multiforme, rash pustular Deep Vein Thrombosis: Deep vein thrombosis, venous thrombosis limb, venous thrombosis Body System Adverse Reaction All Adverse Reactions a Grade 3/4 Adverse Reactions b Rd Continuous (N = 532) Rd18 (N = 540) MPT (N = 541) Rd Continuous (N = 532) Rd18 (N = 540) MPT (N = 541) General disorders and administration site conditions Fatigue % 173 (33) 177 (33) 154 (28) 39 (7) 46 (9) 31 (6) Asthenia 150 (28) 123 (23) 124 (23) 41 (8) 33 (6) 32 (6) Pyrexia c 114 (21) 102 (19) 76 (14) 13 (2) 7 (1) 7 (1) Non-cardiac chest pain f 29 (5) 31 (6) 18 (3) <1% < 1% < 1% Gastrointestinal disorders Diarrhea 242 (45) 208 (39) 89 (16) 21 (4) 18 (3) 8 (1) Abdominal pain % f 109 (20) 78 (14) 60 (11) 7 (1) 9 (2) < 1% Dyspepsia f 57 (11) 28 (5) 36 (7) <1% < 1% 0 (0) Musculoskeletal and connective tissue disorders Back pain c 170 (32) 145 (27) 116 (21) 37 (7) 34 (6) 28 (5) Muscle spasms f 109 (20) 102 (19) 61 (11) < 1% < 1% < 1% Arthralgia f 101 (19) 71 (13) 66 (12) 9 (2) 8 (1) 8 (1) Bone pain f 87 (16) 77 (14) 62 (11) 16 (3) 15 (3) 14 (3) Pain in extremity f 79 (15) 66 (12) 61 (11) 8 (2) 8 (1) 7 (1) Musculoskeletal pain f 67 (13) 59 (11) 36 (7) < 1% < 1% < 1% Musculoskeletal chest pain f 60 (11) 51 (9) 39 (7) 6 (1) < 1% < 1% Muscular weakness f 43 (8) 35 (6) 29 (5) < 1% 8 (1) < 1% Neck pain f 40 (8) 19 (4) 10 (2) < 1% < 1% < 1% Infections and infestations Bronchitis c 90 (17) 59 (11) 43 (8) 9 (2) 6 (1) < 1% Nasopharyngitis f 80 (15) 54 (10) 33 (6) 0 (0) 0 (0) 0 (0) Urinary tract infection f 76 (14) 63 (12) 41 (8) 8 (2) 8 (1) < 1% Upper respiratory tract infection c% f 69 (13) 53 (10) 31 (6) < 1% 8 (1) < 1% Pneumonia c@ 93 (17) 87 (16) 56 (10) 60 (11) 57 (11) 41 (8) Respiratory tract infection % 35 (7) 25 (5) 21 (4) 7 (1) < 1% < 1% Influenza f 33 (6) 23 (4) 15 (3) < 1% < 1% 0 (0) Gastroenteritis f 32 (6) 17 (3) 13 (2) 0 (0) < 1% < 1% Lower respiratory tract infection 29 (5) 14 (3) 16 (3) 10 (2) < 1% < 1% Rhinitis f 29 (5) 24 (4) 14 (3) 0 (0) 0 (0) 0 (0) Cellulitis c < 5% < 5% < 5% 8 (2) < 1% < 1% Sepsis c@ 33 (6) 26 (5) 18 (3) 26 (5) 20 (4) 13 (2) Nervous system disorders Headache f 75 (14) 52 (10) 56 (10) < 1% < 1% < 1% Dysgeusia f 39 (7) 45 (8) 22 (4) < 1% 0 (0.0) < 1% Blood and lymphatic system disorders d Anemia 233 (44) 193 (36) 229 (42) 97 (18) 85 (16) 102 (19) Neutropenia 186 (35) 178 (33) 328 (61) 148 (28) 143 (26) 243 (45) Thrombocytopenia 104 (20) 100 (19) 135 (25) 44 (8) 43 (8) 60 (11) Febrile neutropenia 7 (1) 17 (3) 15 (3) 6 (1) 16 (3) 14 (3) Pancytopenia < 1% 6 (1) 7 (1) < 1% < 1% < 1% Respiratory, thoracic and mediastinal disorders Cough f 121 (23) 94 (17) 68 (13) < 1% < 1% < 1% Dyspnea c,e 117 (22) 89 (16) 113 (21) 30 (6) 22 (4) 18 (3) Epistaxis f 32 (6) 31 (6) 17 (3) < 1% < 1% 0 (0) Oropharyngeal pain f 30 (6) 22 (4) 14 (3) 0 (0) 0 (0) 0 (0) Dyspnea exertional e 27 (5) 29 (5) < 5% 6 (1) < 1% 0 (0) Metabolism and nutrition disorders Decreased appetite 123 (23) 115 (21) 72 (13) 14 (3) 7 (1) < 1% Hypokalemia % 91 (17) 62 (11) 38 (7) 35 (7) 20 (4) 11 (2) Hyperglycemia 62 (12) 52 (10) 19 (4) 28 (5) 23 (4) 9 (2) Hypocalcemia 57 (11) 56 (10) 31 (6) 23 (4) 19 (4) 8 (1) Dehydration % 25 (5) 29 (5) 17 (3) 8 (2) 13 (2) 9 (2) Gout e < 5% < 5% < 5% 8 (2) 0 (0) 0 (0) Diabetes mellitus % e < 5% < 5% < 5% 8 (2) < 1% < 1% Hypophosphatemia e < 5% < 5% < 5% 7 (1) < 1% < 1% Hyponatremia % e < 5% < 5% < 5% 7 (1) 13 (2) 6 (1) Skin and subcutaneous tissue disorders Rash 139 (26) 151 (28) 105 (19) 39 (7) 38 (7) 33 (6) Pruritus f 47 (9) 49 (9) 24 (4) < 1% < 1% < 1% Psychiatric disorders Insomnia 147 (28) 127 (24) 53 (10) < 1% 6 (1) 0 (0) Depression 58 (11) 46 (9) 30 (6) 10 (2) < 1% < 1% Vascular disorders Deep vein thrombosis c% 55 (10) 39 (7) 22 (4) 30 (6) 20 (4) 15 (3) Hypotension c% 51 (10) 35 (6) 36 (7) 11 (2) 8 (1) 6 (1) Injury, Poisoning, and Procedural Complications Fall f 43 (8) 25 (5) 25 (5) < 1% 6 (1) 6 (1) Contusion f 33 (6) 24 (4) 15 (3) < 1% < 1% 0 (0) Eye disorders Cataract 73 (14) 31 (6) < 1% 31 (6) 14 (3) < 1% Cataract subcapsular e < 5% < 5% < 5% 7 (1) 0 (0) 0 (0) Investigations Weight decreased 72 (14) 78 (14) 48 (9) 11 (2) < 1% < 1% Cardiac disorders Atrial fibrillation c 37 (7) 25 (5) 25 (5) 13 (2) 9 (2) 6 (1) Myocardial infarction (including acute) c ,e < 5% < 5% < 5% 10 (2) < 1% < 1% Renal and Urinary disorders Renal failure (including acute) c@,f 49 (9) 54 (10) 37 (7) 28 (5) 33 (6) 29 (5) Neoplasms benign, malignant and unspecified (Including cysts and polyps) Squamous cell carcinoma c e < 5% < 5% < 5% 8 (2) < 1% 0 (0) Basal cell carcinoma c e,f < 5% < 5% < 5% < 1% < 1% 0 (0) Newly Diagnosed MM - REVLIMID Maintenance Therapy Following Auto-HSCT: Data were evaluated from 1018 patients in two randomized trials who received at least one dose of REVLIMID 10 mg daily as maintenance therapy after auto-HSCT until progressive disease or unacceptable toxicity.

The mean treatment duration for REVLIMID treatment was 30.3 months for Maintenance Study 1 and 24.0 months for Maintenance Study 2 (overall range across both studies from 0.1 to 108 months). As of the cut-off date of 1 Mar 2015, 48 patients (21%) in the Maintenance Study 1 REVLIMID arm were still on treatment and none of the patients in the Maintenance Study 2 REVLIMID arm were still on treatment at the same cut-off date The adverse reactions listed from Maintenance Study 1 included events reported post-transplant (completion of high-dose melphalan /auto-HSCT), and the maintenance treatment period.

In Maintenance Study 2, the adverse reactions were from the maintenance treatment period only. In general, the most frequently reported adverse reactions (more than 20% in the REVLIMID arm) across both studies were neutropenia, thrombocytopenia, leukopenia, anemia, upper respiratory tract infection, bronchitis, nasopharyngitis, cough, gastroenteritis, diarrhea, rash, fatigue, asthenia, muscle spasm and pyrexia.

The most frequently reported Grade 3 or 4 reactions (more than 20% in the REVLIMID arm) included neutropenia, thrombocytopenia, and leukopenia. The serious adverse reactions lung infection and neutropenia (more than 4.5%) occurred in the REVLIMID arm. For REVLIMID, the most common adverse reactions leading to dose interruption were hematologic events (29.7%, data available in Maintenance Study 2 only).

The most common adverse reaction leading to dose reduction of REVLIMID were hematologic events (17.7%, data available in Maintenance Study 2 only). The most common adverse reactions leading to discontinuation of REVLIMID were thrombocytopenia (2.7%) in Maintenance Study 1 and neutropenia (2.4%) in Maintenance Study 2. The frequencies of onset of adverse reactions were generally highest in the first 6 months of treatment and then the frequencies decreased over time or remained stable throughout treatment.

Table 5 summarizes the adverse reactions reported for the REVLIMID and placebo maintenance treatment arms. Table 5: All Adverse Reactions in ≥5% and Grade 3/4 Adverse Reactions in ≥1% of Patients with MM in the REVLIMID Vs Placebo Arms* Note: Adverse Events (AEs) are coded to Body System /Adverse Reaction using MedDRA v15.1.

A subject with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse Reaction. a All treatment-emergent AEs in at least 5% of patients in the REVLIMID Maintenance group and at least 2% higher frequency (%) than the Placebo Maintenance group. b All grade 3 or 4 treatment-emergent AEs in at least 1% of patients in the REVLIMID Maintenance group and at least 1% higher frequency (%) than the Placebo Maintenance group. c All serious treatment-emergent AEs in at least 1% of patients in the REVLIMID Maintenance group and at least 1% higher frequency (%) than the Placebo Maintenance group. d Footnote “a” not applicable for either study e Footnote “b” not applicable for either study @ - ADRs where at least one resulted in a fatal outcome % - ADRs where at least one was considered to be Life Threatening (if the outcome of the event was death, it is included with death cases) # - All adverse reactions under Body System of Infections and Infestation except for rare infections of Public Health interest will be considered listed *Adverse Reactions for combined ADR terms (based on relevant TEAE PTs included in Maintenance Studies 1 and 2 [per MedDRA v 15.1]): Pneumonias Bronchopneumonia, Lobar pneumonia, Pneumocystis jiroveci pneumonia, Pneumonia, Pneumonia klebsiella, Pneumonia legionella, Pneumonia mycoplasmal, Pneumonia pneumococcal, Pneumonia streptococcal, Pneumonia viral, Lung disorder, Pneumonitis Sepsis: Bacterial sepsis, Pneumococcal sepsis, Sepsis, Septic shock, Staphylococcal sepsis Peripheral neuropathy: Neuropathy peripheral, Peripheral motor neuropathy, Peripheral sensory neuropathy, Polyneuropathy Deep vein thrombosis: Deep vein thrombosis, Thrombosis, Venous thrombosis Body System Adverse Reaction Maintenance Study 1 Maintenance Study 2 All Adverse Reactions a Grade 3/4 Adverse Reactions b All Adverse Reactions a Grade 3/4 Adverse Reactions b REVLIMID (N=224) n (%) Placebo (N=221) n (%) REVLIMID (N=224) n (%) Placebo (N=221) n (%) REVLIMID (N=293) n (%) Placebo (N=280) n (%) REVLIMID (N=293) n (%) Placebo (N=280) n (%) Blood and lymphatic system disorders Neutropenia c % 177 (79) 94 (43) 133 (59) 73 (33) 178 (61) 33 (12) 158 (54) 21 (8) Thrombocytopenia c % 162 (72) 101 (46) 84 (38) 67 (30) 69 (24) 29 (10) 38 (13) 8 (3) Leukopenia c 51 (23) 25 (11) 45 (20) 22 (10) 93 (32) 21 (8) 71 (24) 5 (2) Anemia 47 (21) 27 (12) 23 (10) 18 (8) 26 (9) 15 (5) 11 (4) 3 (1) Lymphopenia 40 (18) 29 (13) 37 (17) 26 (12) 13 (4) 3 (1) 11 (4) < 1% Pancytopenia c d % < 1% 0 (0) 0 (0) 0 (0) 12 (4) < 1% 7 (2) < 1% Febrile neutropenia c 39 (17) 34 (15) 39 (17) 34 (15) 7 (2) < 1% 5 (2) < 1% Infections and infestations # Upper respiratory tract infection e 60 (27) 35 (16) 7 (3) 9 (4) 32 (11) 18 (6) < 1% 0 (0) Neutropenic infection 40 (18) 19 (9) 27 (12) 14 (6) 0 (0) 0 (0) 0 (0) 0 (0) Pneumonias * c % 31 (14) 15 (7) 23 (10) 7 (3) 50 (17) 13 (5) 27 (9) 5 (2) Bronchitis c 10 (4) 9 (4) < 1% 5 (2) 139 (47) 104 (37) 4 (1) < 1% Nasopharyngitis e 5 (2) < 1% 0 (0) 0 (0) 102 (35) 84 (30) < 1% 0 (0) Gastroenteritis c 0 (0) 0 (0) 0 (0) 0 (0) 66 (23) 55 (20) 6 (2) 0 (0) Rhinitis e < 1% 0 (0) 0 (0) 0 (0) 44 (15) 19 (7) 0 (0) 0 (0) Sinusitis e 8 (4) 3 (1) 0 (0) 0 (0) 41 (14) 26 (9) 0 (0) < 1% Influenza c 8 (4) 5 (2) < 1% < 1% 39 (13) 19 (7) 3 (1) 0 (0) Lung infection c 21 (9) < 1% 19 (8) < 1% 9 (3) 4 (1) < 1% 0 (0) Lower respiratory tract infection e 13 (6) 5 (2) 6 (3) 4 (2) 4 (1) 4 (1) 0 (0) < 1% Infection c 12 (5) 6 (3) 9 (4) 5 (2) 17 (6) 5 (2) 0 (0) 0 (0) Urinary tract infection c d e 9 (4) 5 (2) 4 (2) 4 (2) 22 (8) 17 (6) < 1% 0 (0) Lower respiratory tract infection bacterial d 6 (3) < 1% 4 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Bacteremia d 5 (2) 0 (0) 4 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Herpes zoster c d 11 (5) 10 (5) 3 (1) < 1% 29 (10) 25 (9) 6 (2) < 1% Sepsis * c d @ < 1% < 1% 0 (0) 0 (0) 6 (2) < 1% 4 (1) < 1% Gastrointestinal disorders Diarrhea 122 (54) 83 (38) 22 (10) 17 (8) 114 (39) 34 (12) 7 (2) 0 (0) Nausea e 33 (15) 22 (10) 16 (7) 10 (5) 31 (11) 28 (10) 0 (0) 0 (0) Vomiting 17 (8) 12 (5) 8 (4) 5 (2) 16 (5) 15 (5) < 1% 0 (0) Constipation e 12 (5) 8 (4) 0 (0) 0 (0) 37 (13) 25 (9) < 1% 0 (0) Abdominal pain e 8 (4) 7 (3) < 1% 4 (2) 31 (11) 15 (5) < 1% < 1% Abdominal pain upper e 0 (0) 0 (0) 0 (0) 0 (0) 20 (7) 12 (4) < 1% 0 (0) General disorders and administration site conditions Asthenia 0 (0) < 1% 0 (0) 0 (0) 87 (30) 53 (19) 10 (3) < 1% Fatigue 51 (23) 30 (14) 21 (9) 9 (4) 31 (11) 15 (5) 3 (1) 0 (0) Pyrexia e 17 (8) 10 (5) < 1% < 1% 60 (20) 26 (9) < 1% 0 (0) Skin and subcutaneous tissue disorders Dry skin e 9 (4) 4 (2) 0 (0) 0 (0) 31 (11) 21 (8) 0 (0) 0 (0) Rash 71 (32) 48 (22) 11 (5) 5 (2) 22 (8) 17 (6) 3 (1) 0 (0) Pruritus 9 (4) 4 (2) 3 (1) 0 (0) 21 (7) 25 (9) < 1% 0 (0) Nervous system disorders Paresthesia e < 1% 0 (0) 0 (0) 0 (0) 39 (13) 30 (11) < 1% 0 (0) Peripheral neuropathy * e 34 (15) 30 (14) 8 (4) 8 (4) 29 (10) 15 (5) 4 (1) < 1% Headache d 11 (5) 8 (4) 5 (2) < 1% 25 (9) 21 (8) 0 (0) 0 (0) Investigations Alanine aminotransferase increased 16 (7) 3 (1) 8 (4) 0 (0) 5 (2) 5 (2) 0 (0) < 1% Aspartate aminotransferase increased d 13 (6) 5 (2) 6 (3) 0 (0) < 1% 5 (2) 0 (0) 0 (0) Metabolism and nutrition disorders Hypokalemia 24 (11) 13 (6) 16 (7) 12 (5) 12 (4) < 1% < 1% 0 (0) Dehydration 9 (4) 5 (2) 7 (3) 3 (1) 0 (0) 0 (0) 0 (0) 0 (0) Hypophosphatemia d 16 (7) 15 (7) 13 (6) 14 (6) 0 (0) < 1% 0 (0) 0 (0) Musculoskeletal and connective tissue disorders Muscle spasms e 0 (0) < 1% 0 (0) 0 (0) 98 (33) 43 (15) < 1% 0 (0) Myalgia e 7 (3) 8 (4) 3 (1) 5 (2) 19 (6) 12 (4) < 1% < 1% Musculoskeletal pain e < 1% < 1% 0 (0) 0 (0) 19 (6) 11 (44) 0 (0) 0 (0) Hepatobiliary disorders Hyperbilirubinemia e 34 (15) 19 (9) 4 (2) < 1% 4 (1) < 1% < 1% 0 (0) Respiratory, thoracic and mediastinal disorders Cough e 23 (10) 12 (5) 3 (1) < 1% 80 (27) 56 (20) 0 (0) 0 (0) Dyspnea c e 15 (7) 9 (4) 8 (4) 4 (2) 17 (6) 9 (3) < 1% 0 (0) Rhinorrhea e 0 (0) 3 (1) 0 (0) 0 (0) 15 (5) 6 (2) 0 (0) 0 (0) Pulmonary embolism c d e 0 (0) 0 (0) 0 (0) 0 (0) 3 (1) 0 (0) < 1% 0 (0) Vascular disorders Deep vein thrombosis *c d % 8 (4) < 1% 5 (2) < 1% 7 (2) < 1% 4 (1) < 1% Neoplasms benign, malignant and unspecified (including cysts and polyps) Myelodysplastic syndrome c d e 5 (2) 0 (0) < 1% 0 (0) 3 (1) 0 (0) < 1% 0 (0) After At Least One Prior Therapy for MM: Data were evaluated from 703 patients in two studies who received at least one dose of REVLIMID/dexamethasone (353 patients) or placebo/dexamethasone (350 patients). In the REVLIMID/dexamethasone treatment group, 269 patients (76%) had at least one dose interruption with or without a dose reduction of REVLIMID compared to 199 patients (57%) in the placebo/dexamethasone treatment group.

Of these patients who had one dose interruption with or without a dose reduction, 50% in the REVLIMID/dexamethasone treatment group had at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group. Most adverse reactions and Grade 3/4 adverse reactions were more frequent in patients who received the combination of REVLIMID/dexamethasone compared to placebo/dexamethasone.

Tables 6, 7, and 8 summarize the adverse reactions reported for REVLIMID/dexamethasone and placebo/dexamethasone groups. Table 6: Adverse Reactions Reported in ≥5% of Patients and with a ≥2% Difference in Proportion of Patients with MM between the REVLIMID/dexamethasone and Placebo/dexamethasone Groups Body System Adverse Reaction REVLIMID/Dex (N=353) n (%) Placebo/Dex (N=350) n (%) Blood and lymphatic system disorders Neutropenia % 149 (42) 22 (6) Anemia @ 111 (31) 83 (24) Thrombocytopenia @ 76 (22) 37 (11) Leukopenia 28 (8) 4 (1) Lymphopenia 19 (5) 5 (1) General disorders and administration site conditions Fatigue 155 (44) 146 (42) Pyrexia 97 (27) 82 (23) Peripheral edema 93 (26) 74 (21) Chest pain 29 (8) 20 (6) Lethargy 24 (7) 8 (2) Gastrointestinal disorders Constipation 143 (41) 74 (21) Diarrhea @ 136 (39) 96 (27) Nausea @ 92 (26) 75 (21) Vomiting @ 43 (12) 33 (9) Abdominal pain @ 35 (10) 22 (6) Dry mouth 25 (7) 13 (4) Musculoskeletal and connective tissue disorders Muscle cramp 118 (33) 74 (21) Back pain 91 (26) 65 (19) Bone pain 48 (14) 39 (11) Pain in limb 42 (12) 32 (9) Nervous system disorders Dizziness 82 (23) 59 (17) Tremor 75 (21) 26 (7) Dysgeusia 54 (15) 34 (10) Hypoesthesia 36 (10) 25 (7) Neuropathy a 23 (7) 13 (4) Respiratory, thoracic and mediastinal disorders Dyspnea 83 (24) 60 (17) Nasopharyngitis 62 (18) 31 (9) Pharyngitis 48 (14) 33 (9) Bronchitis 40 (11) 30 (9) Infections b and infestations Upper respiratory tract infection 87 (25) 55 (16) Pneumonia @ 48 (14) 29 (8) Urinary tract infection 30 (8) 19 (5) Sinusitis 26 (7) 16 (5) Skin and subcutaneous system disorders Rash c 75 (21) 33 (9) Sweating increased 35 (10) 25 (7) Dry skin 33 (9) 14 (4) Pruritus 27 (8) 18 (5) Metabolism and nutrition disorders Anorexia 55 (16) 34 (10) Hypokalemia 48 (14) 21 (6) Hypocalcemia 31 (9) 10 (3) Appetite decreased 24 (7) 14 (4) Dehydration 23 (7) 15 (4) Hypomagnesemia 24 (7) 10 (3) Investigations Weight decreased 69 (20) 52 (15) Eye disorders Blurred vision 61 (17) 40 (11) Vascular disorders Deep vein thrombosis % 33 (9) 15 (4) Hypertension 28 (8) 20 (6) Hypotension 25 (7) 15 (4) Table 7: Grade 3/4 Adverse Reactions Reported in ≥2% Patients and with a ≥1% Difference in Proportion of Patients with MM between the REVLIMID/dexamethasone and Placebo/dexamethasone groups Body System Adverse Reaction REVLIMID/Dex (N=353) n (%) Placebo/Dex (N=350) n (%) Blood and lymphatic system disorders Neutropenia % 118 (33) 12 (3) Thrombocytopenia @ 43 (12) 22 (6) Anemia @ 35 (10) 20 (6) Leukopenia 14 (4) < 1% Lymphopenia 10 (3) 4 (1) Febrile neutropenia % 8 (2) 0 (0) General disorders and administration site conditions Fatigue 23 (7) 17 (5) Vascular disorders Deep vein thrombosis % 29 (8) 12 (3) Infections and infestations Pneumonia @ 30 (8) 19 (5) Urinary tract infection 5 (1) < 1% Metabolism and nutrition disorders Hypokalemia 17 (5) 5 (1) Hypocalcemia 13 (4) 6 (2) Hypophosphatemia 9 (3) 0 (0) Respiratory, thoracic and mediastinal disorders Pulmonary embolism @ 14 (4) < 1% Respiratory distress @ 4 (1) 0 (0) Musculoskeletal and connective tissue disorders Muscle weakness 20 (6) 10 (3) Gastrointestinal disorders Diarrhea @ 11 (3) 4 (1) Constipation 7 (2) < 1% Nausea @ 6 (2) < 1% Cardiac disorders Atrial fibrillation @ 13 (4) 4 (1) Tachycardia 6 (2) < 1% Cardiac failure congestive @ 5 (1) < 1% Nervous system disorders Syncope 10 (3) < 1% Dizziness 7 (2) < 1% Eye disorders Cataract 6 (2) < 1% Cataract unilateral 5 (1) 0 (0) Psychiatric disorder Depression 10 (3) 6 (2) Table 8: Serious Adverse Reactions Reported in ≥1% Patients and with a ≥1% Difference in Proportion of Patients with MM between the REVLIMID/dexamethasone and Placebo/dexamethasone Groups Body System Adverse Reaction REVLIMID/Dex (N=353) n (%) Placebo/Dex (N=350) n (%) For Tables 6, 7 and 8 above: @ - adverse reactions in which at least one resulted in a fatal outcome. % - adverse reactions in which at least one was considered to be life threatening (if the outcome of the reaction was death, it is included with death cases).

Blood and lymphatic system disorders Febrile neutropenia % 6 (2) 0 (0) Vascular disorders Deep vein thrombosis % 26 (7) 11 (3) Infections and infestations Pneumonia @ 33 (9) 21 (6) Respiratory, thoracic, and mediastinal disorders Pulmonary embolism @ 13 (4) < 1% Cardiac disorders Atrial fibrillation @ 11 (3) < 1% Cardiac failure congestive @ 5 (1) 0 (0) Nervous system disorders Cerebrovascular accident @ 7 (2) < 1% Gastrointestinal disorders Diarrhea @ 6 (2) < 1% Musculoskeletal and connective tissue disorders Bone pain 4 (1) 0 (0) Median duration of exposure among patients treated with REVLIMID/dexamethasone was 44 weeks while median duration of exposure among patients treated with placebo/dexamethasone was 23 weeks. This should be taken into consideration when comparing frequency of adverse reactions between two treatment groups REVLIMID/dexamethasone vs. placebo/dexamethasone.

Venous and Arterial Thromboembolism [see Boxed Warning, Warnings and Precautions (5.4)] VTE and ATE are increased in patients treated with REVLIMID. Deep vein thrombosis (DVT) was reported as a serious (7.4%) or severe (8.2%) adverse drug reaction at a higher rate in the REVLIMID/dexamethasone group compared to 3.1 % and 3.4% in the placebo/dexamethasone group, respectively in the 2 studies in patients with at least 1 prior therapy with discontinuations due to DVT adverse reactions reported at comparable rates between groups.

In the NDMM study, DVT was reported as an adverse reaction (all grades: 10.3%, 7.2%, 4.1%), as a serious adverse reaction (3.6%, 2.0%, 1.7%), and as a Grade 3/4 adverse reaction (5.6%, 3.7%, 2.8%) in the Rd Continuous, Rd18, and MPT Arms, respectively. Discontinuations and dose reductions due to DVT adverse reactions were reported at comparable rates between the Rd Continuous and Rd18 Arms (both <1%).

Interruption of REVLIMID treatment due to DVT adverse reactions was reported at comparable rates between the Rd Continuous (2.3%) and Rd18 (1.5%) arms. Pulmonary embolism (PE) was reported as a serious adverse drug reaction (3.7%) or Grade 3/4 (4.0%) at a higher rate in the REVLIMID/dexamethasone group compared to 0.9% (serious or grade 3/4) in the placebo/dexamethasone group in the 2 studies in patients with, at least 1 prior therapy, with discontinuations due to PE adverse reactions reported at comparable rates between groups.

In the NDMM study, the frequency of adverse reactions of PE was similar between the Rd Continuous, Rd18, and MPT Arms for adverse reactions (all grades: 3.9%, 3.3%, and 4.3%, respectively), serious adverse reactions (3.8%, 2.8%, and 3.7%, respectively), and grade 3/4 adverse reactions (3.8%, 3.0%, and 3.7%, respectively). Myocardial infarction was reported as a serious (1.7%) or severe (1.7%) adverse drug reaction at a higher rate in the REVLIMID/dexamethasone group compared to 0.6 % and 0.6% respectively in the placebo/dexamethasone group.

Discontinuation due to MI (including acute) adverse reactions was 0.8% in REVLIMID/dexamethasone group and none in the placebo/dexamethasone group. In the NDMM study, myocardial infarction (including acute) was reported as an adverse reaction (all grades: 2.4%, 0.6%, and 1.1%), as a serious adverse reaction, (2.3%, 0.6%, and 1.1%), or as a severe adverse reaction (1.9%, 0.6%, and 0.9%) in the Rd Continuous, Rd18, and MPT Arms, respectively.

Stroke (CVA) was reported as a serious (2.3%) or severe (2.0%) adverse drug reaction in the REVLIMID/dexamethasone group compared to 0.9% and 0.9% respectively in the placebo/dexamethasone group. Discontinuation due to stroke (CVA) was 1.4% in REVLIMID/ dexamethasone group and 0.3% in the placebo/dexamethasone group. In the NDMM study, CVA was reported as an adverse reaction (all grades: 0.8%, 0.6%, and 0.6%), as a serious adverse reaction (0.8%, 0.6 %, and 0.6%), or as a severe adverse reaction (0.6%, 0.6%, 0.2%) in the Rd Continuous, Rd18, and MPT arms respectively.

Other Adverse Reactions: After At Least One Prior Therapy for MM In these 2 studies, the following adverse drug reactions (ADRs) not described above that occurred at ≥1% rate and of at least twice of the placebo percentage rate were reported: Blood and lymphatic system disorders: pancytopenia, autoimmune hemolytic anemia Cardiac disorders: bradycardia, myocardial infarction, angina pectoris Endocrine disorders: hirsutism Eye disorders: blindness, ocular hypertension Gastrointestinal disorders: gastrointestinal hemorrhage, glossodynia General disorders and administration site conditions: malaise Investigations: liver function tests abnormal, alanine aminotransferase increased Nervous system disorders: cerebral ischemia Psychiatric disorders: mood swings, hallucination, loss of libido Reproductive system and breast disorders: erectile dysfunction Respiratory, thoracic and mediastinal disorders: cough, hoarseness Skin and subcutaneous tissue disorders: exanthem, skin hyperpigmentation Myelodysplastic Syndromes: A total of 148 patients received at least 1 dose of 10 mg REVLIMID in the del 5q MDS clinical study. At least one adverse reaction was reported in all of the 148 patients who were treated with the 10 mg starting dose of REVLIMID.

The most frequently reported adverse reactions were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions. Thrombocytopenia (61.5%; 91/148) and neutropenia (58.8%; 87/148) were the most frequently reported adverse reactions.

The next most common adverse reactions observed were diarrhea (48.6%; 72/148), pruritus (41.9%; 62/148), rash (35.8%; 53/148) and fatigue (31.1%; 46/148). Table 9 summarizes the adverse reactions that were reported in ≥ 5% of the REVLIMID treated patients in the del 5q MDS clinical study. Table 10 summarizes the most frequently observed Grade 3 and Grade 4 adverse reactions regardless of relationship to treatment with REVLIMID.

In the single-arm studies conducted, it is often not possible to distinguish adverse reactions that are drug-related and those that reflect the patient's underlying disease. Table 9: Summary of Adverse Reactions Reported in ≥5% of the REVLIMID Treated Patients in del 5q MDS Clinical Study a Body System and adverse reactions are coded using the MedDRA dictionary.

Body System and adverse reactions are listed in descending order of frequency for the Overall column. A patient with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse Reaction. Body System Adverse Reaction a 10 mg Overall (N=148) Patients with at least one adverse reaction 148 (100) Blood and Lymphatic System Disorders Thrombocytopenia 91 (61) Neutropenia 87 (59) Anemia 17 (11) Leukopenia 12 (8) Febrile Neutropenia 8 (5) Skin and Subcutaneous Tissue Disorders Pruritus 62 (42) Rash 53 (36) Dry Skin 21 (14) Contusion 12 (8) Night Sweats 12 (8) Sweating Increased 10 (7) Ecchymosis 8 (5) Erythema 8 (5) Gastrointestinal Disorders Diarrhea 72 (49) Constipation 35 (24) Nausea 35 (24) Abdominal Pain 18 (12) Vomiting 15 (10) Abdominal Pain Upper 12 (8) Dry Mouth 10 (7) Loose Stools 9 (6) Respiratory, Thoracic and Mediastinal Disorders Nasopharyngitis 34 (23) Cough 29 (20) Dyspnea 25 (17) Pharyngitis 23 (16) Epistaxis 22 (15) Dyspnea Exertional 10 (7) Rhinitis 10 (7) Bronchitis 9 (6) General Disorders and Administration Site Conditions Fatigue 46 (31) Pyrexia 31 (21) Edema Peripheral 30 (20) Asthenia 22 (15) Edema 15 (10) Pain 10 (7) Rigors 9 (6) Chest Pain 8 (5) Musculoskeletal and Connective Tissue Disorders Arthralgia 32 (22) Back Pain 31 (21) Muscle Cramp 27 (18) Pain in Limb 16 (11) Myalgia 13 (9) Peripheral Swelling 12 (8) Nervous System Disorders Dizziness 29 (20) Headache 29 (20) Hypoesthesia 10 (7) Dysgeusia 9 (6) Peripheral Neuropathy 8 (5) Infections and Infestations Upper Respiratory Tract Infection 22 (15) Pneumonia 17 (11) Urinary Tract Infection 16 (11) Sinusitis 12 (8) Cellulitis 8 (5) Metabolism and Nutrition Disorders Hypokalemia 16 (11) Anorexia 15 (10) Hypomagnesemia 9 (6) Investigations Alanine Aminotransferase Increased 12 (8) Psychiatric Disorders Insomnia 15 (10) Depression 8 (5) Renal and Urinary Disorders Dysuria 10 (7) Vascular Disorders Hypertension 9 (6) Endocrine Disorders Acquired Hypothyroidism 10 (7) Cardiac Disorders Palpitations 8 (5) Table 10: Most Frequently Observed Grade 3 and 4 Adverse Reactions 1 Regardless of Relationship to Study Drug Treatment in the del 5q MDS Clinical Study 1 Adverse reactions with frequency ≥1% in the 10 mg Overall group.

Grade 3 and 4 are based on National Cancer Institute Common Toxicity Criteria version 2. 2 Adverse reactions are coded using the MedDRA dictionary. A patient with multiple occurrences of an adverse reaction is counted only once in the adverse reaction category. Adverse Reactions 2 10 mg (N=148) Patients with at least one Grade 3/4 AE 131 (89) Neutropenia 79 (53) Thrombocytopenia 74 (50) Pneumonia 11 (7) Rash 10 (7) Anemia 9 (6) Leukopenia 8 (5) Fatigue 7 (5) Dyspnea 7 (5) Back Pain 7 (5) Febrile Neutropenia 6 (4) Nausea 6 (4) Diarrhea 5 (3) Pyrexia 5 (3) Sepsis 4 (3) Dizziness 4 (3) Granulocytopenia 3 (2) Chest Pain 3 (2) Pulmonary Embolism 3 (2) Respiratory Distress 3 (2) Pruritus 3 (2) Pancytopenia 3 (2) Muscle Cramp 3 (2) Respiratory Tract Infection 2 (1) Upper Respiratory Tract Infection 2 (1) Asthenia 2 (1) Multi-organ Failure 2 (1) Epistaxis 2 (1) Hypoxia 2 (1) Pleural Effusion 2 (1) Pneumonitis 2 (1) Pulmonary Hypertension 2 (1) Vomiting 2 (1) Sweating Increased 2 (1) Arthralgia 2 (1) Pain in Limb 2 (1) Headache 2 (1) Syncope 2 (1) In other clinical studies of REVLIMID in MDS patients, the following serious adverse reactions (regardless of relationship to study drug treatment) not described in Table 9 or 10 were reported: Blood and lymphatic system disorders: warm type hemolytic anemia, splenic infarction, bone marrow depression, coagulopathy, hemolysis, hemolytic anemia, refractory anemia Cardiac disorders: cardiac failure congestive, atrial fibrillation, angina pectoris, cardiac arrest, cardiac failure, cardio-respiratory arrest, cardiomyopathy, myocardial infarction, myocardial ischemia, atrial fibrillation aggravated, bradycardia, cardiogenic shock, pulmonary edema, supraventricular arrhythmia, tachyarrhythmia, ventricular dysfunction Ear and labyrinth disorders: vertigo Endocrine disorders: Basedow's disease Gastrointestinal disorders: gastrointestinal hemorrhage, colitis ischemic, intestinal perforation, rectal hemorrhage, colonic polyp, diverticulitis, dysphagia, gastritis, gastroenteritis, gastroesophageal reflux disease, obstructive inguinal hernia, irritable bowel syndrome, melena, pancreatitis due to biliary obstruction, pancreatitis, perirectal abscess, small intestinal obstruction, upper gastrointestinal hemorrhage General disorders and administration site conditions: disease progression, fall, gait abnormal, intermittent pyrexia, nodule, rigors, sudden death Hepatobiliary disorders: hyperbilirubinemia, cholecystitis, acute cholecystitis, hepatic failure Immune system disorders: hypersensitivity Infections and infestations: infection bacteremia, central line infection, clostridial infection, ear infection, Enterobacter sepsis, fungal infection, herpes viral infection NOS, influenza, kidney infection, Klebsiella sepsis, lobar pneumonia, localized infection, oral infection, Pseudomonas infection, septic shock, sinusitis acute, sinusitis, Staphylococcal infection, urosepsis Injury, poisoning and procedural complications: femur fracture, transfusion reaction, cervical vertebral fracture, femoral neck fracture, fractured pelvis, hip fracture, overdose, post procedural hemorrhage, rib fracture, road traffic accident, spinal compression fracture Investigations: blood creatinine increased, hemoglobin decreased, liver function tests abnormal, troponin I increased Metabolism and nutrition disorders: dehydration, gout, hypernatremia, hypoglycemia Musculoskeletal and connective tissue disorders: arthritis, arthritis aggravated, gouty arthritis, neck pain, chondrocalcinosis pyrophosphate Neoplasms benign, malignant and unspecified: acute leukemia, acute myeloid leukemia, bronchoalveolar carcinoma, lung cancer metastatic, lymphoma, prostate cancer metastatic Nervous system disorders: cerebrovascular accident, aphasia, cerebellar infarction, cerebral infarction, depressed level of consciousness, dysarthria, migraine, spinal cord compression, subarachnoid hemorrhage, transient ischemic attack Psychiatric disorders: confusional state Renal and urinary disorders: renal failure, hematuria, renal failure acute, azotemia, calculus ureteric, renal mass Reproductive system and breast disorders: pelvic pain Respiratory, thoracic and mediastinal disorders: bronchitis, chronic obstructive airways disease exacerbated, respiratory failure, dyspnea exacerbated, interstitial lung disease, lung infiltration, wheezing Skin and subcutaneous tissue disorders: acute febrile neutrophilic dermatosis Vascular system disorders: deep vein thrombosis, hypotension, aortic disorder, ischemia, thrombophlebitis superficial, thrombosis Mantle Cell Lymphoma: In the MCL trial, a total of 134 patients received at least 1 dose of REVLIMID.

Their median age was 67 (range 43-83) years, 128/134 (96%) were Caucasian, 108/134 (81%) were males and 82/134 (61%) had duration of MCL for at least 3 years. Table 11 summarizes the most frequently observed adverse reactions regardless of relationship to treatment with REVLIMID. Across the 134 patients treated in this study, median duration of treatment was 95 days (1-1002 days).

Seventy-eight patients (58%) received 3 or more cycles of therapy, 53 patients (40%) received 6 or more cycles, and 26 patients (19%) received 12 or more cycles. Seventy-six patients (57%) underwent at least one dose interruption due to adverse reactions, and 51 patients (38%) underwent at least one dose reduction due to adverse reactions.

Twenty-six patients (19%) discontinued treatment due to adverse reactions. Table 11: Incidence of Adverse Reactions (≥10%) or Grade 3 / 4 AE (in at least 2 patients) in Mantle Cell Lymphoma 1 -MCL trial AEs – All treatment emergent AEs with ≥10% of subjects. 2 -MCL trial Grade 3/4 AEs – All treatment-emergent Grade 3/4 AEs in 2 or more subjects. $ -MCL trial Serious AEs – All treatment-emergent SAEs in 2 or more subjects. @ - Adverse reactions where at least one resulted in a fatal outcome. % - Adverse reactions where at least one was considered to be Life Threatening (if the outcome of the event was death, it is included with death cases). # - All adverse reactions under Body System of Infections except for rare infections of Public Health interest will be considered listed. + - All adverse reactions under HLT of Rash will be considered listed.

Body System Adverse Reaction All Adverse Reactions 1 (N=134) n (%) Grade 3/4 Adverse Reactions 2 (N=134) n (%) General disorders and administration site conditions Fatigue 45 (34) 9 (7) Pyrexia $ 31 (23) 3 (2) Edema peripheral 21 (16) 0 Asthenia $ 19 (14) 4 (3) General physical health deterioration 3 (2) 2 (1) Gastrointestinal disorders Diarrhea $ 42 (31) 8 (6) Nausea $ 40 (30) 1 (<1) Constipation 21 (16) 1 (<1) Vomiting $ 16 (12) 1 (<1) Abdominal pain $ 13 (10) 5 (4) Musculoskeletal and connective tissue disorders Back pain 18 (13) 2 (1) Muscle spasms 17 (13) 1 (<1) Arthralgia 11 (8) 2 (1) Muscular weakness $ 8 (6) 2 (1) Respiratory, thoracic and mediastinal disorders Cough 38 (28) 1 (<1) Dyspnea $ 24 (18) 8 (6) Pleural Effusion 10 (7) 2 (1) Hypoxia 3 (2) 2 (1) Pulmonary embolism 3 (2) 2 (1) Respiratory distress $ 2 (1) 2 (1) Oropharyngeal pain 13 (10) 0 Infections and infestations Pneumonia @ $ 19 (14) 12 (9) Upper respiratory tract infection 17 (13) 0 Cellulitis $ 3 (2) 2 (1) Bacteremia $ 2 (1) 2 (1) Staphylococcal sepsis $ 2 (1) 2 (1) Urinary tract infection $ 5 (4) 2 (1) Skin and subcutaneous tissue disorders Rash + 30 (22) 2 (1) Pruritus 23 (17) 1 (<1) Blood and lymphatic system disorders Neutropenia 65 (49) 58 (43) Thrombocytopenia % $ 48 (36) 37 (28) Anemia $ 41 (31) 15 (11) Leukopenia $ 20 (15) 9 (7) Lymphopenia 10 (7) 5 (4) Febrile neutropenia $ 8 (6) 8 (6) Metabolism and nutrition disorders Decreased appetite 19 (14) 1 (<1) Hypokalemia 17 (13) 3 (2) Dehydration $ 10 (7) 4 (3) Hypocalcemia 4 (3) 2 (1) Hyponatremia 3 (2) 3 (2) Renal and urinary disorders Renal failure $ 5 (4) 2 (1) Vascular disorders Hypotension @ $ 9 (7) 4 (3) Deep vein thrombosis $ 5 (4) 5 (4) Neoplasms benign, malignant and unspecified (including cysts and polyps) Tumor flare 13 (10) 0 Squamous cell carcinoma of skin $ 4 (3) 4 (3) Investigations Weight decreased 17 (13) 0 The following adverse reactions which have occurred in other indications including another MCL study and not described above have been reported (1%-10%) in patients treated with REVLIMID monotherapy for mantle cell lymphoma. Cardiac disorder: Cardiac failure Ear and labyrinth disorders: Vertigo General disorders and administration site conditions: Chills Infections and infestations: Respiratory tract infection, sinusitis, nasopharyngitis, oral herpes Musculoskeletal and connective tissue disorders: Pain in extremity Nervous system disorders: Dysgeusia, headache, neuropathy peripheral, lethargy Psychiatric disorders: Insomnia Skin and subcutaneous tissue disorders: Dry skin, night sweats The following serious adverse reactions not described above and reported in 2 or more patients treated with REVLIMID monotherapy for mantle cell lymphoma.

Blood and lymphatic system disorders: Neutropenia Cardiac disorder: Myocardial infarction (including acute MI), supraventricular tachycardia Infections and infestations: Clostridium difficile colitis, sepsis Neoplasms benign, malignant and unspecified (including cysts and polyps): Basal cell carcinoma Respiratory, thoracic, and mediastinal disorders: Chronic obstructive pulmonary disease, pulmonary embolism Follicular Lymphoma or Marginal Zone Lymphoma The safety of REVLIMID/ rituximab was evaluated in 398 patients with either previously treated follicular lymphoma or marginal zone lymphoma in two clinical trials; AUGMENT (N=176) and MAGNIFY (N=222) [see Clinical Studies (14.4)]. Subjects were 18 years or older in age, had an ECOG PS ≤2, ANC ≥1,000 cells/mm 3 and platelets≥ 75,000/mm 3 (unless secondary to bone marrow involvement by lymphoma), hemoglobin ≥8g/dL, AST and ALT ≤ 3 x ULN (unless documented liver involvement with lymphoma, and creatinine clearance of ≥ 30mL/min.

Subjects with active HIV, hepatitis B or C were not eligible. In the AUGMENT trial, patients received REVLIMID 20 mg daily by mouth on days 1 – 21 of each 28 day cycle with rituximab 375 mg/m 2 weekly (days 1, 8, 15 and 22 in cycle 1) then on day 1 of cycles 2-5 (n=176) or placebo with rituximab 375 mg/m 2 weekly (days 1, 8, 15 and 22 in cycle 1) then on day 1 of cycles 2-5 (n=180) for up to 12 cycles.

In the MAGNIFY trial, patients received REVLIMID 20 mg by mouth daily, days 1-21 of each 28 day cycle with rituximab 375 mg/m 2 weekly (days 1, 8, 15 and 22 in cycle 1) then on day 1 of cycles 3, 5, 7, 9 and 11 in the induction phase of the trial (n=222). In the AUGMENT trial, 88.1% of patients completed at least 6 cycles of REVLIMID/rituximab, and 71% of patients completed 12 cycles.

In the ongoing MAGNIFY trial as of May 1, 2017, 62.2% of patients completed at least 6 cycles of REVLIMID/rituximab, and 30.6% of patients completed 12 cycles. Across both clinical trials (AUGMENT and MAGNIFY), patients had a median age of 64.5 years (26 to 91); 49% were male; and 81% were White. Fatal adverse reactions occurred in 6 patients (1.5%) receiving REVLIMID/rituximab.

Fatal adverse reactions (1 each) included cardio-respiratory arrest, arrhythmia, cardiopulmonary failure, multiple organ dysfunction syndrome, sepsis, and acute kidney injury. Serious adverse reactions occurred in 26% of patients receiving REVLIMID/rituximab in AUGMENT and 29% in MAGNIFY. The most frequent serious adverse reaction that occurred in ≥ 2.5% of patients in the REVLIMID/rituximab arm was febrile neutropenia (3%).

Permanent discontinuation of REVLIMID or rituximab due to an adverse reaction occurred in 14.6% of patients in the REVLIMID/rituximab arm. The most common adverse reaction (in at least 1%) requiring permanent discontinuation of REVLIMID or rituximab was neutropenia (4.8%). The most common adverse reactions occurring in at least 20% of subjects were; neutropenia (48%), fatigue (37%), diarrhea (32%), constipation (27%), nausea (21%), and cough (20%).

Table 12: All Grade Adverse Reactions (≥5%) or Grade 3/4 Adverse Reactions (≥1%) in Patients with FL and MZL with a Difference Between Arms of >1% When Compared to Control Arm in AUGMENT Trial Note: Adverse reactions are coded to body system/adverse reaction using MedDRA 21. A patient with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse reaction. 1 All treatment-emergent AEs in at least 5% of patients in the REVLIMID + rituximab group and at least 1% higher frequency (%) than the rituximab + placebo group (control arm). 2 All grade 3 or 4 treatment-emergent AEs in at least 1% of patients in the REVLIMID + rituximab group and at least 1% higher frequency (%) than the rituximab + placebo group (control arm). 3 All serious treatment-emergent AEs in at least 1% of patients in the REVLIMID + rituximab group and at least 1% higher frequency (%) than the rituximab + placebo group (control arm). $ Serious ADR reported. @ - adverse reactions in which at least one resulted in a fatal outcome. % - adverse reactions in which at least one was considered to be life threatening (if the outcome of the reaction was death, it is included with death cases). *Adverse Reactions for combined ADR terms (based on relevant TEAE PTs [per MedDRA version 21.0]): a "Thromboembolic events" combined term includes the following PTs: pulmonary embolism, deep vein thrombosis, cerebrovascular accident, embolism, and thrombosis. b "Cough" combined AE term includes the following PTs: cough and productive cough. c “Abdominal pain” combined AE term includes the following PTs: abdominal pain and abdominal pain upper. d "Rash" combined AE term includes the following PTs: rash maculo-papular, rash erythematous, rash macular, rash papular, rash pruritic, and rash generalized. e "Pruritus" combined AE term includes the following PTs: pruritus, pruritus generalized, rash pruritic, and pruritus allergic.

All Adverse Reactions 1 Grade 3 / 4 Adverse Reactions 2 Body System Adverse Reaction * REVLIMID + Rituximab Arm (N=176) n (%) Rituximab + Placebo (Control Arm) (N=180) n (%) REVLIMID + Rituximab Arm (N=176) n (%) Rituximab + Placebo (Control Arm) (N=180) n (%) Infections and infestations Upper respiratory tract infection 32 (18) 23 (13) 2 (1.1) 4 (2.2) Influenza % 17 (10) 8 (4.4) 1 (< 1) 0 (0) Pneumonia 3,$,% 13 (7) 6 (3.3) 6 (3.4) 4 (2.2) Sinusitis 13 (7) 5 (2.8) 0 (0) 0 (0) Urinary tract infection $ 13 (7) 7 (3.9) 1 (< 1) 1 (< 1) Bronchitis 8 (4.5) 6 (3.3) 2 (1.1) 0 (0) Gastroenteritis $ 6 (3.4) 4 (2.2) 2 (1.1) 0 (0) Neoplasms benign, malignant and unspecified (including cysts and polyps) Tumor flare $ 19 (11) 1 (< 1) 1 (< 1) 0 (0) Blood and lymphatic disorders Neutropenia 3,$, % 102 (58) 40 (22) 88 (50) 23 (13) Leukopenia $,% 36 (20) 17 (9) 12 (7) 3 (1.7) Anemia 3,$ 28 (16) 8 (4.4) 8 (4.5) 1 (< 1) Thrombocytopenia 3,$,% 26 (15) 8 (4.4) 4 (2.3) 2 (1.1) Lymphopenia 8 (4.5) 14 (8) 5 (2.8) 2 (1.1) Febrile Neutropenia 3,$,% 5 (2.8) 1 (< 1) 5 (2.8) 1 (< 1) Metabolism and nutrition disorders Decreased Appetite 23 (13) 11 (6) 2 (1.1) 0 (0) Hypokalemia % 14 (8) 5 (2.8) 4 (2.3) 0 (0) Hyperuricemia 10 (6) 8 (4.4) 1 (< 1) 1 (< 1) Nervous system disorders Headache 26 (15) 17 (9) 1 (< 1) 0 (0) Dizziness 15 (9) 9 (5) 0 (0) 0 (0) Vascular disorders Hypotension % 9 (5) 1 (< 1) 1 (< 1) 0 (0) Thromboembolic events a,$ 8 (4.5) 2 (1.1) 4 (2.3) 2 (1.1) Respiratory, thoracic and mediastinal disorders Cough b 43 (24) 35 (19) 1 (< 1) 0 (0) Dyspnea $ 19 (11) 8 (4.4) 2 (1.1) 1 (< 1) Oropharyngeal pain 10 (6) 8 (4.4) 0 (0) 0 (0) Pulmonary Embolism 3,$ 4 (2.3) 1 (< 1) 4 (2.3) 1 (< 1) Chronic obstructive pulmonary disease $ 3 (1.7) 0 (0) 2 (1.1) 0 (0) Respiratory failure 3,$ 2 (1.1) 1 (< 1) 2 (1.1) 0 (0) Gastrointestinal disorders Diarrhea $,% 55 (31) 41 (23) 5 (2.8) 0 (0) Constipation 46 (26) 25 (14) 0 (0) 0 (0) Abdominal pain c ,$ 32 (18) 20 (11) 2 (1.1) 0 (0) Vomiting $ 17 (10) 13 (7) 0 (0) 0 (0) Dyspepsia 16 (9) 5 (2.8) 0 (0) 0 (0) Stomatitis 9 (5) 7 (3.9) 0 (0) 0 (0) Skin and subcutaneous tissue disorders Rash $,d 39 (22) 14 (8) 5 (2.8) 2 (1.1) Pruritus $,e 36 (20) 9 (5) 2 (1.1) 0 (0) Dry skin 9 (5) 6 (3.3) 0 (0) 0 (0) Dermatitis acneiform 8 (4.5) 0 (0) 2 (1.1) 0 (0) Musculoskeletal and connective tissue disorders Muscle Spasms 23 (13) 9 (5) 1 (< 1) 1 (< 1) Pain in Extremity $ 8 (4.5) 9 (5) 2 (1) 0 (0) Renal disorders Acute Kidney Injury 3,$,@,% 3 (1.7) 0 (0) 2 (1.1) 0 (0) Cardiac disorders Supraventricular tachycardia 3,$ 2 (1.1) 0 (0) 2 (1.1) 0 (0) General disorders and administration site conditions Fatigue 38 (22) 33 (18) 2 (1.1) 1 (< 1) Pyrexia 3,$ 37 (21) 27 (15) 1 (< 1) 3 (1.7) Asthenia $,% 24 (14) 19 (11) 2 (1.1) 1 (< 1) Edema Peripheral $ 23 (13) 16 (9) 0 (0) 0 (0) Chills 14 (8) 8 (4.4) 0 (0) 0 (0) Malaise 13 (7) 10 (6) 0 (0) 0 (0) Influenza like illness 9 (5) 7 (3.9) 0 (0) 0 (0) Psychiatric disorders Insomnia 14 (8) 11 (6) 0 (0) 0 (0) Investigations Alanine Aminotransferase Increased 18 (10) 15 (8) 3 (1.7) 1 (< 1) WBC count decreased 16 (9) 13 (7) 5 (2.8) 2 (1.1) Lymphocyte count decreased 12 (7) 12 (7) 6 (3.4) 2 (1.1) Blood bilirubin increased 10 (6) 0 (0) 0 (0) 0 (0) Weight Decreased 12 (7) 2 (1.1) 0 (0) 0 (0)

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse drug reactions have been identified from the worldwide post-marketing experience with REVLIMID. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure [see Warnings and Precautions Section (5.8 to 5.11, and 5.13)] Endocrine disorders: Hypothyroidism, hyperthyroidism Hepatobiliary disorders: Hepatic failure (including fatality), toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis, mixed cytolytic/cholestatic hepatitis, transient abnormal liver laboratory tests Immune system disorders: Angioedema, anaphylaxis, acute graft-versus-host disease (following allogeneic hematopoietic transplant), solid organ transplant rejection Infections and infestations: Viral reactivation (such as hepatitis B virus and herpes zoster), progressive multifocal leukoencephalopathy (PML) Neoplasms benign, malignant and unspecified (including cysts and polyps): Tumor lysis syndrome, tumor flare reaction Respiratory, thoracic and mediastinal disorders: Pneumonitis Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)

Adverse reaction frequency tables (US label) US FDA label
Table 4: All Adverse Reactions in ≥5% and Grade 3/4 Adverse Reactions in ≥1% of Patients with MM in the Rd Continuous or Rd18 Arms*
Note: A subject with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse Reaction. a All treatment-emergent adverse events in at least 5% of subjects in the Rd Continuous or Rd18 Arms and at least a 2% higher frequency (%) in either the Rd Continuous or Rd18 Arms compared to the MPT Arm. b All grade 3 or 4 treatment-emergent adverse events in at least 1% of subjects in the Rd Continuous or Rd18 Arms and at least a 1% higher frequency (%) in either the Rd Continuous or Rd18 Arms compared to the MPT Arm. c Serious treatment-emergent adverse events in at least 1% of subjects in the Rd Continuous or Rd18 Arms and at least a 1% higher frequency (%) in either the Rd Continuous or Rd18 Arms compared to the MPT Arm. d Preferred terms for the blood and lymphatic system disorders body system were included by medical judgment as known adverse reactions for Rd Continuous/Rd18, and have also been reported as serious. e Footnote “a” not applicable. f Footnote “b” not applicable. @ - adverse reactions in which at least one resulted in a fatal outcome. % - adverse reactions in which at least one was considered to be life threatening (if the outcome of the reaction was death, it is included with death cases). *Adverse reactions included in combined adverse reaction terms: Abdominal Pain: Abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain Pneumonias: Pneumonia, lobar pneumonia, pneumonia pneumococcal, bronchopneumonia, pneumocystis jiroveci pneumonia, pneumonia legionella, pneumonia staphylococcal, pneumonia klebsiella, atypical pneumonia, pneumonia bacterial, pneumonia escherichia, pneumonia streptococcal, pneumonia viral Sepsis: Sepsis, septic shock, urosepsis, escherichia sepsis, neutropenic sepsis, pneumococcal sepsis, staphylococcal sepsis, bacterial sepsis, meningococcal sepsis, enterococcal sepsis, klebsiella sepsis, pseudomonal sepsis Rash: Rash, rash pruritic, rash erythematous, rash maculo-papular, rash generalized, rash papular, exfoliative rash, rash follicular, rash macular, drug rash with eosinophilia and systemic symptoms, erythema multiforme, rash pustular Deep Vein Thrombosis: Deep vein thrombosis, venous thrombosis limb, venous thrombosis
Body System Adverse ReactionAll Adverse ReactionsaGrade 3/4 Adverse Reactionsb
Rd Continuous (N = 532)Rd18 (N = 540)MPT (N = 541)Rd Continuous (N = 532)Rd18 (N = 540)MPT (N = 541)
General disorders and administration site conditions
Fatigue%173 (33)177 (33)154 (28)39 ( 7)46 ( 9)31 ( 6)
Asthenia150 (28)123 (23)124 (23)41 ( 8)33 ( 6)32 ( 6)
Pyrexiac114 (21)102 (19)76 (14)13 ( 2)7 ( 1)7 ( 1)
Non-cardiac chest pain f29 ( 5)31 ( 6)18 ( 3)<1%< 1%< 1%
Gastrointestinal disorders
Diarrhea242 (45)208 (39)89 (16)21 ( 4)18 ( 3)8 ( 1)
Abdominal pain% f109 (20)78 (14)60 (11)7 ( 1)9 ( 2)< 1%
Dyspepsia f57 (11)28 ( 5)36 ( 7)<1%< 1%0 ( 0)
Musculoskeletal and connective tissue disorders
Back painc170 (32)145 (27)116 (21)37 ( 7)34 ( 6)28 ( 5)
Muscle spasms f109 (20)102 (19)61 (11)< 1%< 1%< 1%
Arthralgia f101 (19)71 (13)66 (12)9 ( 2)8 ( 1)8 ( 1)
Bone pain f87 (16)77 (14)62 (11)16 ( 3)15 ( 3)14 ( 3)
Pain in extremity f79 (15)66 (12)61 (11)8 ( 2)8 ( 1)7 ( 1)
Musculoskeletal pain f67 (13)59 (11)36 ( 7)< 1%< 1%< 1%
Musculoskeletal chest pain f60 (11)51 ( 9)39 ( 7)6 ( 1)< 1%< 1%
Muscular weakness f43 ( 8)35 ( 6)29 ( 5)< 1%8 ( 1)< 1%
Neck pain f40 ( 8)19 ( 4)10 ( 2)< 1%< 1%< 1%
Infections and infestations
Bronchitisc90 (17)59 (11)43 ( 8)9 ( 2)6 ( 1)< 1%
Nasopharyngitis f80 (15)54 (10)33 ( 6)0 ( 0)0 ( 0)0 ( 0)
Urinary tract infection f76 (14)63 (12)41 ( 8)8 ( 2)8 ( 1)< 1%
Upper respiratory tract infectionc% f69 (13)53 ( 10)31 ( 6)< 1%8 ( 1)< 1%
Pneumoniac@93 (17)87 (16)56 (10)60 (11)57 (11)41 ( 8)
Respiratory tract infection%35 ( 7)25 ( 5)21 ( 4)7 ( 1)< 1%< 1%
Influenza f33 ( 6)23 ( 4)15 ( 3)< 1%< 1%0 ( 0)
Gastroenteritis f32 ( 6)17 ( 3)13 ( 2)0 ( 0)< 1%< 1%
Lower respiratory tract infection29 ( 5)14 ( 3)16 ( 3)10 ( 2)< 1%< 1%
Rhinitis f29 ( 5)24 ( 4)14 ( 3)0 ( 0)0 ( 0)0 ( 0)
Cellulitisc< 5%< 5%< 5%8 ( 2)< 1%< 1%
Sepsisc@33 ( 6)26 ( 5)18 ( 3)26 ( 5)20 ( 4)13 ( 2)
Nervous system disorders
Headache f 75 (14)52 ( 10)56 (10)< 1%< 1%< 1%
Dysgeusia f39 ( 7)45 ( 8)22 ( 4)< 1%0 ( 0.0)< 1%
Blood and lymphatic system disordersd
Anemia233 (44)193 (36)229 (42)97 (18)85 (16)102 (19)
Neutropenia186 (35)178 (33)328 (61)148 (28)143 (26)243 (45)
Thrombocytopenia104 (20)100 (19)135 (25)44 ( 8)43 ( 8)60 (11)
Febrile neutropenia7 ( 1)17 ( 3)15 ( 3)6 ( 1)16 ( 3)14 ( 3)
Pancytopenia< 1%6 ( 1)7 ( 1)< 1%< 1%< 1%
Respiratory, thoracic and mediastinal disorders
Cough f121 (23)94 (17)68 (13)< 1%< 1%< 1%
Dyspneac,e117 (22)89 (16)113 (21)30 ( 6)22 ( 4)18 ( 3)
Epistaxis f32 ( 6)31 ( 6)17 ( 3)< 1%< 1%0 ( 0)
Oropharyngeal pain f30 ( 6)22 ( 4)14 ( 3)0 ( 0)0 ( 0)0 ( 0)
Dyspnea exertional e27 ( 5)29 ( 5)< 5%6 ( 1)< 1%0 ( 0)
Metabolism and nutrition disorders
Decreased appetite123 (23)115 (21)72 (13)14 ( 3)7 ( 1)< 1%
Hypokalemia%91 (17)62 (11)38 ( 7)35 ( 7)20 ( 4)11 ( 2)
Hyperglycemia62 (12)52 (10)19 ( 4)28 ( 5)23 ( 4)9 ( 2)
Hypocalcemia57 (11)56 (10)31 ( 6)23 ( 4)19 ( 4)8 ( 1)
Dehydration%25 ( 5)29 ( 5)17 ( 3)8 ( 2)13 ( 2)9 ( 2)
Gout e< 5%< 5%< 5%8 ( 2)0 ( 0)0 ( 0)
Diabetes mellitus% e< 5%< 5%< 5%8 ( 2)< 1%< 1%
Hypophosphatemia e< 5%< 5%< 5%7 ( 1)< 1%< 1%
Hyponatremia% e< 5%< 5%< 5%7 ( 1)13 ( 2)6 ( 1)
Skin and subcutaneous tissue disorders
Rash139 (26)151 (28)105 (19)39 ( 7)38 ( 7)33 ( 6)
Pruritus f47 ( 9)49 ( 9)24 ( 4)< 1%< 1%< 1%
Psychiatric disorders
Insomnia147 (28)127 (24)53 ( 10)< 1%6 ( 1)0 ( 0)
Depression58 (11)46 ( 9)30 ( 6)10 ( 2)< 1%< 1%
Vascular disorders
Deep vein thrombosisc% 55 (10)39 ( 7)22 ( 4)30 ( 6)20 ( 4)15 ( 3)
Hypotensionc% 51 (10)35 ( 6)36 ( 7)11 ( 2)8 ( 1)6 ( 1)
Injury, Poisoning, and Procedural Complications
Fall f43 ( 8)25 ( 5)25 ( 5)< 1%6 ( 1)6 ( 1)
Contusion f33 ( 6)24 ( 4)15 ( 3)< 1%< 1%0 ( 0)
Eye disorders
Cataract73 (14)31 ( 6)< 1%31 ( 6)14 ( 3)< 1%
Cataract subcapsular e< 5%< 5%< 5%7 ( 1)0 ( 0)0 ( 0)
Investigations
Weight decreased72 (14)78 (14)48 ( 9)11 ( 2)< 1%< 1%
Cardiac disorders
Atrial fibrillationc37 ( 7)25 ( 5)25 ( 5)13 ( 2)9 ( 2)6 ( 1)
Myocardial infarction (including acute)c ,e< 5%< 5%< 5%10 ( 2)< 1%< 1%
Renal and Urinary disorders
Renal failure (including acute)c@,f 49 ( 9)54 (10)37 ( 7)28 ( 5)33 ( 6)29 ( 5)
Neoplasms benign, malignant and unspecified (Including cysts and polyps)
Squamous cell carcinomac e< 5%< 5%< 5%8 ( 2)< 1%0 ( 0)
Basal cell carcinomac e,f< 5%< 5%< 5%< 1%< 1%0 ( 0)
Table 5: All Adverse Reactions in ≥5% and Grade 3/4 Adverse Reactions in ≥1% of Patients with MM in the REVLIMID Vs Placebo Arms*
Note: Adverse Events (AEs) are coded to Body System /Adverse Reaction using MedDRA v15.1. A subject with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse Reaction. a All treatment-emergent AEs in at least 5% of patients in the REVLIMID Maintenance group and at least 2% higher frequency (%) than the Placebo Maintenance group. b All grade 3 or 4 treatment-emergent AEs in at least 1% of patients in the REVLIMID Maintenance group and at least 1% higher frequency (%) than the Placebo Maintenance group. c All serious treatment-emergent AEs in at least 1% of patients in the REVLIMID Maintenance group and at least 1% higher frequency (%) than the Placebo Maintenance group. d Footnote “a” not applicable for either study e Footnote “b” not applicable for either study @ - ADRs where at least one resulted in a fatal outcome % - ADRs where at least one was considered to be Life Threatening (if the outcome of the event was death, it is included with death cases) # - All adverse reactions under Body System of Infections and Infestation except for rare infections of Public Health interest will be considered listed *Adverse Reactions for combined ADR terms (based on relevant TEAE PTs included in Maintenance Studies 1 and 2 [per MedDRA v 15.1]): Pneumonias Bronchopneumonia, Lobar pneumonia, Pneumocystis jiroveci pneumonia, Pneumonia, Pneumonia klebsiella, Pneumonia legionella, Pneumonia mycoplasmal, Pneumonia pneumococcal, Pneumonia streptococcal, Pneumonia viral, Lung disorder, Pneumonitis Sepsis: Bacterial sepsis, Pneumococcal sepsis, Sepsis, Septic shock, Staphylococcal sepsis Peripheral neuropathy: Neuropathy peripheral, Peripheral motor neuropathy, Peripheral sensory neuropathy, Polyneuropathy Deep vein thrombosis: Deep vein thrombosis, Thrombosis, Venous thrombosis
Body System Adverse ReactionMaintenance Study 1Maintenance Study 2
All Adverse Reactions aGrade 3/4 Adverse Reactions bAll Adverse Reactions aGrade 3/4 Adverse Reactions b
REVLIMID (N=224) n (%)Placebo (N=221) n (%)REVLIMID (N=224) n (%)Placebo (N=221) n (%)REVLIMID (N=293) n (%)Placebo (N=280) n (%)REVLIMID (N=293) n (%)Placebo (N=280) n (%)
Blood and lymphatic system disorders
Neutropenia c %177 ( 79)94 ( 43)133 ( 59)73 ( 33)178 ( 61)33 ( 12)158 ( 54)21 ( 8)
Thrombocytopenia c %162 ( 72)101 ( 46)84 ( 38)67 ( 30)69 ( 24)29 ( 10)38 ( 13)8 ( 3)
Leukopenia c51 ( 23)25 ( 11)45 ( 20)22 ( 10)93 ( 32)21 ( 8)71 ( 24)5 ( 2)
Anemia47 ( 21)27 ( 12)23 ( 10)18 ( 8)26 ( 9)15 ( 5)11 ( 4)3 ( 1)
Lymphopenia40 ( 18)29 ( 13)37 ( 17)26 ( 12)13 ( 4)3 ( 1)11 ( 4)< 1%
Pancytopenia c d %< 1%0 ( 0)0 ( 0)0 ( 0)12 ( 4)< 1%7 ( 2)< 1%
Febrile neutropenia c39 ( 17)34 ( 15)39 ( 17)34 ( 15)7 ( 2)< 1%5 ( 2)< 1%
Infections and infestations#
Upper respiratory tract infection e60 ( 27)35 ( 16)7 ( 3)9 ( 4)32 ( 11)18 ( 6)< 1%0 ( 0)
Neutropenic infection40 ( 18)19 ( 9)27 ( 12)14 ( 6)0 ( 0)0 ( 0)0 ( 0)0 ( 0)
Pneumonias* c %31 ( 14)15 ( 7)23 ( 10)7 ( 3)50 ( 17)13 ( 5)27 ( 9)5 ( 2)
Bronchitis c10 ( 4)9 ( 4)< 1%5 ( 2)139 ( 47)104 ( 37)4 ( 1)< 1%
Nasopharyngitis e5 ( 2)< 1%0 ( 0)0 ( 0)102 ( 35)84 ( 30)< 1%0 ( 0)
Gastroenteritis c0 ( 0)0 ( 0)0 ( 0)0 ( 0)66 ( 23)55 ( 20)6 ( 2)0 ( 0)
Rhinitis e< 1%0 ( 0)0 ( 0)0 ( 0)44 ( 15)19 ( 7)0 ( 0)0 ( 0)
Sinusitis e8 ( 4)3 ( 1)0 ( 0)0 ( 0)41 ( 14)26 ( 9)0 ( 0)< 1%
Influenza c8 ( 4)5 ( 2)< 1%< 1%39 ( 13)19 ( 7)3 ( 1)0 ( 0)
Lung infection c21 ( 9)< 1%19 ( 8)< 1%9 ( 3)4 ( 1)< 1%0 ( 0)
Lower respiratory tract infection e13 ( 6)5 ( 2)6 ( 3)4 ( 2)4 ( 1)4 ( 1)0 ( 0)< 1%
Infection c12 ( 5)6 ( 3)9 ( 4)5 ( 2)17 ( 6)5 ( 2)0 ( 0)0 ( 0)
Urinary tract infection c d e9 ( 4)5 ( 2)4 ( 2)4 ( 2)22 ( 8)17 ( 6)< 1%0 ( 0)
Lower respiratory tract infection bacterial d6 ( 3)< 1%4 ( 2)0 ( 0)0 ( 0)0 ( 0)0 ( 0)0 ( 0)
Bacteremia d5 ( 2)0 ( 0)4 ( 2)0 ( 0)0 ( 0)0 ( 0)0 ( 0)0 ( 0)
Herpes zoster c d11 ( 5)10 ( 5)3 ( 1)< 1%29 ( 10)25 ( 9)6 ( 2)< 1%
Sepsis* c d @< 1%< 1%0 ( 0)0 ( 0)6 ( 2)< 1%4 ( 1)< 1%
Gastrointestinal disorders
Diarrhea122 ( 54)83 ( 38)22 ( 10)17 ( 8)114 ( 39)34 ( 12)7 ( 2)0 ( 0)
Nausea e33 ( 15)22 ( 10)16 ( 7)10 ( 5)31 ( 11)28 ( 10)0 ( 0)0 ( 0)
Vomiting17 ( 8)12 ( 5)8 ( 4)5 ( 2)16 ( 5)15 ( 5)< 1%0 ( 0)
Constipation e12 ( 5)8 ( 4)0 ( 0)0 ( 0)37 ( 13)25 ( 9)< 1%0 ( 0)
Abdominal pain e8 ( 4)7 ( 3)< 1%4 ( 2)31 ( 11)15 ( 5)< 1%< 1%
Abdominal pain upper e0 ( 0)0 ( 0)0 ( 0)0 ( 0)20 ( 7)12 ( 4)< 1%0 ( 0)
General disorders and administration site conditions
Asthenia0 ( 0)< 1%0 ( 0)0 ( 0)87 ( 30)53 ( 19)10 ( 3)< 1%
Fatigue51 ( 23)30 ( 14)21 ( 9)9 ( 4)31 ( 11)15 ( 5)3 ( 1)0 ( 0)
Pyrexia e17 ( 8)10 ( 5)< 1%< 1%60 ( 20)26 ( 9)< 1%0 ( 0)
Skin and subcutaneous tissue disorders
Dry skin e9 ( 4)4 ( 2)0 ( 0)0 ( 0)31 ( 11)21 ( 8)0 ( 0)0 ( 0)
Rash71 ( 32)48 ( 22)11 ( 5)5 ( 2)22 ( 8)17 ( 6)3 ( 1)0 ( 0)
Pruritus9 ( 4)4 ( 2)3 ( 1)0 ( 0)21 ( 7)25 ( 9)< 1%0 ( 0)
Nervous system disorders
Paresthesia e< 1%0 ( 0)0 ( 0)0 ( 0)39 ( 13)30 ( 11)< 1%0 ( 0)
Peripheral neuropathy* e34 ( 15)30 ( 14)8 ( 4)8 ( 4)29 ( 10)15 ( 5)4 ( 1)< 1%
Headache d11 ( 5)8 ( 4)5 ( 2)< 1%25 ( 9)21 ( 8)0 ( 0)0 ( 0)
Investigations
Alanine aminotransferase increased16 ( 7)3 ( 1)8 ( 4)0 ( 0)5 ( 2)5 ( 2)0 ( 0)< 1%
Aspartate aminotransferase increased d13 ( 6)5 ( 2)6 ( 3)0 ( 0)< 1%5 ( 2)0 ( 0)0 ( 0)
Metabolism and nutrition disorders
Hypokalemia24 ( 11)13 ( 6)16 ( 7)12 ( 5)12 ( 4)< 1%< 1%0 ( 0)
Dehydration9 ( 4 )5 ( 2)7 ( 3)3 ( 1)0 ( 0)0 ( 0)0 ( 0)0 ( 0)
Hypophosphatemia d16 ( 7)15 ( 7)13 ( 6)14 ( 6)0 ( 0)< 1%0 ( 0)0 ( 0)
Musculoskeletal and connective tissue disorders
Muscle spasms e0 ( 0)< 1%0 ( 0)0 ( 0)98 ( 33)43 ( 15)< 1%0 ( 0)
Myalgia e7 ( 3)8 ( 4)3 ( 1)5 ( 2)19 ( 6)12 ( 4)< 1%< 1%
Musculoskeletal pain e< 1%< 1%0 ( 0)0 ( 0)19 ( 6)11 ( 44)0 ( 0)0 ( 0)
Hepatobiliary disorders
Hyperbilirubinemia e34 ( 15)19 ( 9)4 ( 2)< 1%4 ( 1)< 1%< 1%0 ( 0)
Respiratory, thoracic and mediastinal disorders
Cough e23 ( 10)12 ( 5)3 ( 1)< 1%80 ( 27)56 ( 20)0 ( 0)0 ( 0)
Dyspnea c e15 ( 7)9 ( 4)8 ( 4)4 ( 2)17 ( 6)9 ( 3)< 1%0 ( 0)
Rhinorrhea e0 ( 0)3 ( 1)0 ( 0)0 ( 0)15 ( 5)6 ( 2)0 ( 0)0 ( 0)
Pulmonary embolism c d e0 ( 0)0 ( 0)0 ( 0)0 ( 0)3 ( 1)0 ( 0)< 1%0 ( 0)
Vascular disorders
Deep vein thrombosis*c d %8 ( 4)< 1%5 ( 2)< 1%7 ( 2)< 1%4 ( 1)< 1%
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Myelodysplastic syndrome c d e5 ( 2)0 ( 0)< 1%0 ( 0)3 ( 1)0 ( 0)< 1%0 ( 0)
Table 6: Adverse Reactions Reported in ≥5% of Patients and with a ≥2% Difference in Proportion of Patients with MM between the REVLIMID/dexamethasone and Placebo/dexamethasone Groups
Body System Adverse ReactionREVLIMID/Dex (N=353) n (%)Placebo/Dex (N=350) n (%)
Blood and lymphatic system disorders
Neutropenia%149 (42)22 ( 6)
Anemia@111 (31)83 (24)
Thrombocytopenia@76 (22)37 (11)
Leukopenia28 ( 8)4 ( 1)
Lymphopenia19 ( 5)5 ( 1)
General disorders and administration site conditions
Fatigue155 (44)146 (42)
Pyrexia97 (27)82 (23)
Peripheral edema93 (26)74 (21)
Chest pain29 ( 8)20 ( 6)
Lethargy24 ( 7)8 ( 2)
Gastrointestinal disorders
Constipation143 (41)74 (21)
Diarrhea@136 (39)96 (27)
Nausea@92 (26)75 (21)
Vomiting@43 (12)33 ( 9)
Abdominal pain@35 ( 10)22 ( 6)
Dry mouth25 ( 7)13 ( 4)
Musculoskeletal and connective tissue disorders
Muscle cramp118 (33)74 (21)
Back pain91 (26)65 (19)
Bone pain48 (14)39 (11)
Pain in limb42 (12)32 ( 9)
Nervous system disorders
Dizziness82 (23)59 (17)
Tremor75 (21)26 ( 7)
Dysgeusia54 (15)34 ( 10)
Hypoesthesia36 (10)25 ( 7)
Neuropathya23 ( 7)13 ( 4)
Respiratory, thoracic and mediastinal disorders
Dyspnea83 (24)60 (17)
Nasopharyngitis62 (18)31 ( 9)
Pharyngitis48 (14)33 ( 9)
Bronchitis 40 (11)30 ( 9)
Infectionsb and infestations
Upper respiratory tract infection 87 (25)55 (16)
Pneumonia@48 (14)29 ( 8)
Urinary tract infection30 ( 8)19 ( 5)
Sinusitis26 ( 7)16 ( 5)
Skin and subcutaneous system disorders
Rashc75 (21)33 ( 9)
Sweating increased35 ( 10)25 ( 7)
Dry skin33 ( 9)14 ( 4)
Pruritus27 ( 8)18 ( 5)
Metabolism and nutrition disorders
Anorexia55 (16)34 ( 10)
Hypokalemia48 (14)21 ( 6)
Hypocalcemia31 ( 9)10 ( 3)
Appetite decreased 24 ( 7)14 ( 4)
Dehydration23 ( 7)15 ( 4)
Hypomagnesemia24 ( 7)10 ( 3)
Investigations
Weight decreased69 (20)52 (15)
Eye disorders
Blurred vision61 (17)40 (11)
Vascular disorders
Deep vein thrombosis%33 ( 9)15 ( 4)
Hypertension28 ( 8)20 ( 6)
Hypotension25 ( 7)15 ( 4)
Table 7: Grade 3/4 Adverse Reactions Reported in ≥2% Patients and with a ≥1% Difference in Proportion of Patients with MM between the REVLIMID/dexamethasone and Placebo/dexamethasone groups
Body System Adverse ReactionREVLIMID/Dex (N=353) n (%)Placebo/Dex (N=350) n (%)
Blood and lymphatic system disorders
Neutropenia%118 (33)12 ( 3)
Thrombocytopenia@43 (12)22 ( 6)
Anemia@35 ( 10)20 ( 6)
Leukopenia14 ( 4)< 1%
Lymphopenia10 ( 3)4 ( 1)
Febrile neutropenia%8 ( 2)0 ( 0)
General disorders and administration site conditions
Fatigue23 ( 7)17 ( 5)
Vascular disorders
Deep vein thrombosis%29 ( 8)12 ( 3)
Infections and infestations
Pneumonia@30 ( 8)19 ( 5)
Urinary tract infection 5 ( 1)< 1%
Metabolism and nutrition disorders
Hypokalemia17 ( 5)5 ( 1)
Hypocalcemia13 ( 4)6 ( 2)
Hypophosphatemia9 ( 3)0 ( 0)
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism@14 ( 4)< 1%
Respiratory distress@4 ( 1)0 ( 0)
Musculoskeletal and connective tissue disorders
Muscle weakness 20 ( 6)10 ( 3)
Gastrointestinal disorders
Diarrhea@11 ( 3)4 ( 1)
Constipation7 ( 2)< 1%
Nausea@6 ( 2)< 1%
Cardiac disorders
Atrial fibrillation@13 ( 4)4 ( 1)
Tachycardia 6 ( 2)< 1%
Cardiac failure congestive@5 ( 1)< 1%
Nervous system disorders
Syncope10 ( 3)< 1%
Dizziness7 ( 2)< 1%
Eye disorders
Cataract6 ( 2)< 1%
Cataract unilateral5 ( 1)0 ( 0)
Psychiatric disorder
Depression10 ( 3)6 ( 2)
Table 8: Serious Adverse Reactions Reported in ≥1% Patients and with a ≥1% Difference in Proportion of Patients with MM between the REVLIMID/dexamethasone and Placebo/dexamethasone Groups
Body System Adverse ReactionREVLIMID/Dex (N=353) n (%)Placebo/Dex (N=350) n (%)
For Tables 6, 7 and 8 above: @ - adverse reactions in which at least one resulted in a fatal outcome. % - adverse reactions in which at least one was considered to be life threatening (if the outcome of the reaction was death, it is included with death cases).
Blood and lymphatic system disorders
Febrile neutropenia%6 ( 2)0 ( 0)
Vascular disorders
Deep vein thrombosis%26 ( 7)11 ( 3)
Infections and infestations
Pneumonia@33 ( 9)21 ( 6)
Respiratory, thoracic, and mediastinal disorders
Pulmonary embolism@13 ( 4)< 1%
Cardiac disorders
Atrial fibrillation@11 ( 3)< 1%
Cardiac failure congestive@5 ( 1)0 ( 0)
Nervous system disorders
Cerebrovascular accident@7 ( 2)< 1%
Gastrointestinal disorders
Diarrhea @6 ( 2)< 1%
Musculoskeletal and connective tissue disorders
Bone pain4 ( 1)0 ( 0)
Table 9: Summary of Adverse Reactions Reported in ≥5% of the REVLIMID Treated Patients in del 5q MDS Clinical Study
a Body System and adverse reactions are coded using the MedDRA dictionary. Body System and adverse reactions are listed in descending order of frequency for the Overall column. A patient with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse Reaction.
Body System Adverse Reaction a10 mg Overall (N=148)
Patients with at least one adverse reaction148 (100)
Blood and Lymphatic System Disorders
Thrombocytopenia91 (61)
Neutropenia87 (59)
Anemia17 (11)
Leukopenia12 (8)
Febrile Neutropenia8 (5)
Skin and Subcutaneous Tissue Disorders
Pruritus62 (42)
Rash53 (36)
Dry Skin21 (14)
Contusion12 (8)
Night Sweats12 (8)
Sweating Increased10 (7)
Ecchymosis8 (5)
Erythema8 (5)
Gastrointestinal Disorders
Diarrhea72 (49)
Constipation35 (24)
Nausea35 (24)
Abdominal Pain18 (12)
Vomiting15 (10)
Abdominal Pain Upper12 (8)
Dry Mouth10 (7)
Loose Stools9 (6)
Respiratory, Thoracic and Mediastinal Disorders
Nasopharyngitis34 (23)
Cough29 (20)
Dyspnea25 (17)
Pharyngitis23 (16)
Epistaxis22 (15)
Dyspnea Exertional10 (7)
Rhinitis10 (7)
Bronchitis9 (6)
General Disorders and Administration Site Conditions
Fatigue46 (31)
Pyrexia31 (21)
Edema Peripheral30 (20)
Asthenia22 (15)
Edema 15 (10)
Pain10 (7)
Rigors 9 (6)
Chest Pain8 (5)
Musculoskeletal and Connective Tissue Disorders
Arthralgia32 (22)
Back Pain 31 (21)
Muscle Cramp27 (18)
Pain in Limb16 (11)
Myalgia13 (9)
Peripheral Swelling12 (8)
Nervous System Disorders
Dizziness 29 (20)
Headache 29 (20)
Hypoesthesia10 (7)
Dysgeusia9 (6)
Peripheral Neuropathy8 (5)
Infections and Infestations
Upper Respiratory Tract Infection22 (15)
Pneumonia17 (11)
Urinary Tract Infection16 (11)
Sinusitis12 (8)
Cellulitis8 (5)
Metabolism and Nutrition Disorders
Hypokalemia16 (11)
Anorexia15 (10)
Hypomagnesemia9 (6)
Investigations
Alanine Aminotransferase Increased12 (8)
Psychiatric Disorders
Insomnia15 (10)
Depression8 (5)
Renal and Urinary Disorders
Dysuria10 (7)
Vascular Disorders
Hypertension9 (6)
Endocrine Disorders
Acquired Hypothyroidism10 (7)
Cardiac Disorders
Palpitations8 (5)
Table 10: Most Frequently Observed Grade 3 and 4 Adverse Reactions 1 Regardless of Relationship to Study Drug Treatment in the del 5q MDS Clinical Study
1 Adverse reactions with frequency ≥1% in the 10 mg Overall group. Grade 3 and 4 are based on National Cancer Institute Common Toxicity Criteria version 2. 2 Adverse reactions are coded using the MedDRA dictionary. A patient with multiple occurrences of an adverse reaction is counted only once in the adverse reaction category.
Adverse Reactions 210 mg (N=148)
Patients with at least one Grade 3/4 AE131 (89)
Neutropenia79 (53)
Thrombocytopenia74 (50)
Pneumonia11 (7)
Rash10 (7)
Anemia9 (6)
Leukopenia8 (5)
Fatigue7 (5)
Dyspnea7 (5)
Back Pain7 (5)
Febrile Neutropenia6 (4)
Nausea6 (4)
Diarrhea5 (3)
Pyrexia5 (3)
Sepsis4 (3)
Dizziness4 (3)
Granulocytopenia3 (2)
Chest Pain3 (2)
Pulmonary Embolism3 (2)
Respiratory Distress3 (2)
Pruritus3 (2)
Pancytopenia3 (2)
Muscle Cramp3 (2)
Respiratory Tract Infection2 (1)
Upper Respiratory Tract Infection2 (1)
Asthenia2 (1)
Multi-organ Failure2 (1)
Epistaxis2 (1)
Hypoxia2 (1)
Pleural Effusion2 (1)
Pneumonitis2 (1)
Pulmonary Hypertension2 (1)
Vomiting2 (1)
Sweating Increased2 (1)
Arthralgia2 (1)
Pain in Limb2 (1)
Headache2 (1)
Syncope2 (1)
Table 11: Incidence of Adverse Reactions (≥10%) or Grade 3 / 4 AE (in at least 2 patients) in Mantle Cell Lymphoma
1-MCL trial AEs – All treatment emergent AEs with ≥10% of subjects. 2-MCL trial Grade 3/4 AEs – All treatment-emergent Grade 3/4 AEs in 2 or more subjects. $-MCL trial Serious AEs – All treatment-emergent SAEs in 2 or more subjects. @ - Adverse reactions where at least one resulted in a fatal outcome. % - Adverse reactions where at least one was considered to be Life Threatening (if the outcome of the event was death, it is included with death cases). # - All adverse reactions under Body System of Infections except for rare infections of Public Health interest will be considered listed. + - All adverse reactions under HLT of Rash will be considered listed.
Body System Adverse ReactionAll Adverse Reactions1 (N=134) n (%)Grade 3/4 Adverse Reactions2 (N=134) n (%)
General disorders and administration site conditions
Fatigue45 (34)9 (7)
Pyrexia$31 (23)3 (2)
Edema peripheral 21 (16)0
Asthenia$19 (14)4 (3)
General physical health deterioration3 (2)2 (1)
Gastrointestinal disorders
Diarrhea$42 (31)8 (6)
Nausea$40 (30)1 (<1)
Constipation 21 (16)1 (<1)
Vomiting$16 (12)1 (<1)
Abdominal pain$13 (10)5 ( 4)
Musculoskeletal and connective tissue disorders
Back pain 18 (13)2 (1)
Muscle spasms 17 (13)1 (<1)
Arthralgia 11 (8)2 (1)
Muscular weakness$8 (6)2 ( 1)
Respiratory, thoracic and mediastinal disorders
Cough 38 (28)1 (<1)
Dyspnea$24 (18)8 (6)
Pleural Effusion10 (7)2 (1)
Hypoxia3 (2)2 (1)
Pulmonary embolism 3 (2)2 ( 1)
Respiratory distress$2 (1)2 (1)
Oropharyngeal pain13 (10)0
Infections and infestations
Pneumonia@ $19 (14)12 (9)
Upper respiratory tract infection 17 (13)0
Cellulitis$3 (2)2 (1)
Bacteremia$2 (1)2 (1)
Staphylococcal sepsis$2 (1)2 (1)
Urinary tract infection$5 (4)2 (1)
Skin and subcutaneous tissue disorders
Rash +30 (22)2 (1)
Pruritus23 (17)1 (<1)
Blood and lymphatic system disorders
Neutropenia65 (49)58 (43)
Thrombocytopenia% $48 (36)37 (28)
Anemia$41 (31)15 (11)
Leukopenia$20 (15)9 (7)
Lymphopenia10 ( 7)5 (4)
Febrile neutropenia$8 (6)8 (6)
Metabolism and nutrition disorders
Decreased appetite 19 (14)1 (<1)
Hypokalemia17 (13)3 (2)
Dehydration$10 (7)4 (3)
Hypocalcemia4 (3)2 (1)
Hyponatremia3 (2)3 (2)
Renal and urinary disorders
Renal failure$5 (4)2 (1)
Vascular disorders
Hypotension@ $9 (7)4 (3)
Deep vein thrombosis$5 (4)5 (4)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Tumor flare13 (10)0
Squamous cell carcinoma of skin$4 (3)4 (3)
Investigations
Weight decreased 17 (13)0
Table 12: All Grade Adverse Reactions ( ≥5%) or Grade 3/4 Adverse Reactions ( ≥1%) in Patients with FL and MZL with a Difference Between Arms of >1% When Compared to Control Arm in AUGMENT Trial
Note: Adverse reactions are coded to body system/adverse reaction using MedDRA 21. A patient with multiple occurrences of an adverse reaction is counted only once under the applicable Body System/Adverse reaction. 1 All treatment-emergent AEs in at least 5% of patients in the REVLIMID + rituximab group and at least 1% higher frequency (%) than the rituximab + placebo group (control arm). 2 All grade 3 or 4 treatment-emergent AEs in at least 1% of patients in the REVLIMID + rituximab group and at least 1% higher frequency (%) than the rituximab + placebo group (control arm). 3 All serious treatment-emergent AEs in at least 1% of patients in the REVLIMID + rituximab group and at least 1% higher frequency (%) than the rituximab + placebo group (control arm). $ Serious ADR reported. @ - adverse reactions in which at least one resulted in a fatal outcome. % - adverse reactions in which at least one was considered to be life threatening (if the outcome of the reaction was death, it is included with death cases). *Adverse Reactions for combined ADR terms (based on relevant TEAE PTs [per MedDRA version 21.0]): a "Thromboembolic events" combined term includes the following PTs: pulmonary embolism, deep vein thrombosis, cerebrovascular accident, embolism, and thrombosis. b "Cough" combined AE term includes the following PTs: cough and productive cough.
c “Abdominal pain” combined AE term includes the following PTs: abdominal pain and abdominal pain upper. d "Rash" combined AE term includes the following PTs: rash maculo-papular, rash erythematous, rash macular, rash papular, rash pruritic, and rash generalized. e "Pruritus" combined AE term includes the following PTs: pruritus, pruritus generalized, rash pruritic, and pruritus allergic.
All Adverse Reactions 1Grade 3 / 4 Adverse Reactions 2
Body System Adverse Reaction*REVLIMID + Rituximab Arm (N=176) n (%)Rituximab + Placebo (Control Arm) (N=180) n (%)REVLIMID + Rituximab Arm (N=176) n (%)Rituximab + Placebo (Control Arm) (N=180) n (%)
Infections and infestations
Upper respiratory tract infection32 (18)23 (13)2 (1.1)4 (2.2)
Influenza %17 (10)8 (4.4)1 (< 1)0 (0)
Pneumonia 3,$,%13 (7)6 (3.3)6 (3.4)4 (2.2)
Sinusitis13 (7)5 (2.8)0 (0)0 (0)
Urinary tract infection$13 (7)7 (3.9)1 (< 1)1 (< 1)
Bronchitis8 (4.5)6 (3.3)2 (1.1)0 (0)
Gastroenteritis $6 (3.4)4 (2.2)2 (1.1)0 (0)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Tumor flare $19 (11)1 (< 1)1 (< 1)0 (0)
Blood and lymphatic disorders
Neutropenia 3,$, %102 (58)40 (22)88 (50)23 (13)
Leukopenia $,%36 (20)17 (9)12 (7)3 (1.7)
Anemia 3,$28 (16)8 (4.4)8 (4.5)1 (< 1)
Thrombocytopenia 3,$,%26 (15)8 (4.4)4 (2.3)2 (1.1)
Lymphopenia8 (4.5)14 (8)5 (2.8)2 (1.1)
Febrile Neutropenia 3,$,%5 (2.8)1 (< 1)5 (2.8)1 (< 1)
Metabolism and nutrition disorders
Decreased Appetite23 (13)11 (6)2 (1.1)0 (0)
Hypokalemia %14 (8)5 (2.8)4 (2.3)0 (0)
Hyperuricemia10 (6)8 (4.4)1 (< 1)1 (< 1)
Nervous system disorders
Headache26 (15)17 (9)1 (< 1)0 (0)
Dizziness15 (9)9 (5)0 (0)0 (0)
Vascular disorders
Hypotension %9 (5)1 (< 1)1 (< 1)0 (0)
Thromboembolic events a,$8 (4.5)2 (1.1)4 (2.3)2 (1.1)
Respiratory, thoracic and mediastinal disorders
Cough b43 (24)35 (19)1 (< 1)0 (0)
Dyspnea $19 (11)8 (4.4)2 (1.1)1 (< 1)
Oropharyngeal pain10 (6)8 (4.4)0 (0)0 (0)
Pulmonary Embolism 3,$4 (2.3)1 (< 1)4 (2.3)1 (< 1)
Chronic obstructive pulmonary disease $3 (1.7)0 (0)2 (1.1)0 (0)
Respiratory failure 3,$2 (1.1)1 (< 1)2 (1.1)0 (0)
Gastrointestinal disorders
Diarrhea $,%55 (31)41 (23)5 (2.8)0 (0)
Constipation46 (26)25 (14)0 (0)0 (0)
Abdominal pain c ,$32 (18)20 (11)2 (1.1)0 (0)
Vomiting $17 (10)13 (7)0 (0)0 (0)
Dyspepsia16 (9)5 (2.8)0 (0)0 (0)
Stomatitis9 (5)7 (3.9)0 (0)0 (0)
Skin and subcutaneous tissue disorders
Rash $,d39 (22)14 (8)5 (2.8)2 (1.1)
Pruritus $,e36 (20)9 (5)2 (1.1)0 (0)
Dry skin9 (5)6 (3.3)0 (0)0 (0)
Dermatitis acneiform8 (4.5)0 (0)2 (1.1)0 (0)
Musculoskeletal and connective tissue disorders
Muscle Spasms23 (13)9 (5)1 (< 1)1 (< 1)
Pain in Extremity $8 (4.5)9 (5)2 (1)0 (0)
Renal disorders
Acute Kidney Injury 3,$,@,%3 (1.7)0 (0)2 (1.1)0 (0)
Cardiac disorders
Supraventricular tachycardia 3,$2 (1.1)0 (0)2 (1.1)0 (0)
General disorders and administration site conditions
Fatigue38 (22)33 (18)2 (1.1)1 (< 1)
Pyrexia 3,$37 (21)27 (15)1 (< 1)3 (1.7)
Asthenia $,%24 (14)19 (11)2 (1.1)1 (< 1)
Edema Peripheral $23 (13)16 (9)0 (0)0 (0)
Chills14 (8)8 (4.4)0 (0)0 (0)
Malaise13 (7)10 (6)0 (0)0 (0)
Influenza like illness9 (5)7 (3.9)0 (0)0 (0)
Psychiatric disorders
Insomnia14 (8)11 (6)0 (0)0 (0)
Investigations
Alanine Aminotransferase Increased18 (10)15 (8)3 (1.7)1 (< 1)
WBC count decreased16 (9)13 (7)5 (2.8)2 (1.1)
Lymphocyte count decreased12 (7)12 (7)6 (3.4)2 (1.1)
Blood bilirubin increased10 (6)0 (0)0 (0)0 (0)
Weight Decreased12 (7)2 (1.1)0 (0)0 (0)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in females exposed to REVLIMID during pregnancy as well as female partners of male patients who are exposed to REVLIMID. This registry is also used to understand the root cause for the pregnancy. Report any suspected fetal exposure to REVLIMID to the FDA via the MedWatch program at 1-800-FDA-1088 and also to the REMS Call Center at 1-888-423-5436.

Risk Summary Based on the mechanism of action [see Clinical Pharmacology (12.1)] and findings from animal studies [see Data], REVLIMID can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy [see Boxed Warning, Contraindications (4.1), and Use in Specific Populations (5.1)]. REVLIMID is a thalidomide analogue.

Thalidomide is a human teratogen, inducing a high frequency of severe and life-threatening birth defects such as amelia (absence of limbs), phocomelia (short limbs), hypoplasticity of the bones, absence of bones, external ear abnormalities (including anotia, micropinna, small or absent external auditory canals), facial palsy, eye abnormalities (anophthalmos, microphthalmos), and congenital heart defects. Alimentary tract, urinary tract, and genital malformations have also been documented and mortality at or shortly after birth has been reported in about 40% of infants.

Lenalidomide caused thalidomide-type limb defects in monkey offspring. Lenalidomide crossed the placenta after administration to pregnant rabbits and pregnant rats [see Data]. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus.

If pregnancy does occur during treatment, immediately discontinue the drug. Under these conditions, refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Report any suspected fetal exposure to REVLIMID to the FDA via the MedWatch program at 1-800-FDA-1088 and also to the REMS Call Center at 1-888-423-5436.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk in the U.S. general population of major birth defects is 2%-4% and of miscarriage is 15%-20% of clinically recognized pregnancies.

Data Animal data In an embryo-fetal developmental toxicity study in monkeys, teratogenicity, including thalidomide-like limb defects, occurred in offspring when pregnant monkeys received oral lenalidomide during organogenesis. Exposure (AUC) in monkeys at the lowest dose was 0.17 times the human exposure at the maximum recommended human dose (MRHD) of 25 mg.

Similar studies in pregnant rabbits and rats at 20 times and 200 times the MRHD respectively, produced embryo lethality in rabbits and no adverse reproductive effects in rats. In a pre- and post-natal development study in rats, animals received lenalidomide from organogenesis through lactation. The study revealed a few adverse effects on the offspring of female rats treated with lenalidomide at doses up to 500 mg/kg (approximately 200 times the human dose of 25 mg based on body surface area).

The male offspring exhibited slightly delayed sexual maturation and the female offspring had slightly lower body weight gains during gestation when bred to male offspring. As with thalidomide, the rat model may not adequately address the full spectrum of potential human embryo-fetal developmental effects for lenalidomide.

Following daily oral administration of lenalidomide from Gestation Day 7 through Gestation Day 20 in pregnant rabbits, fetal plasma lenalidomide concentrations were approximately 20-40% of the maternal C max. Following a single oral dose to pregnant rats, lenalidomide was detected in fetal plasma and tissues; concentrations of radioactivity in fetal tissues were generally lower than those in maternal tissues.

These data indicated that lenalidomide crossed the placenta.

Mechanism of action

12.1 Mechanism of Action Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects.

Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes, follicular lymphoma and marginal zone lymphoma in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including MM.

Immunomodulatory properties of lenalidomide include increased number and activation of T cells and natural killer (NK) cells leading to direct and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via increased secretion of interleukin-2 and interferon-gamma, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In MM cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.

The combination of lenalidomide and rituximab increases ADCC and direct tumor apoptosis in follicular lymphoma cells and increases ADCC in marginal zone lymphoma cells compared to rituximab alone in vitro.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Cardiac Electrophysiology The effect of lenalidomide on the QTc interval was evaluated in 60 healthy male subjects in a thorough QT study. At a dose two times the maximum recommended dose, lenalidomide did not prolong the QTc interval. The largest upper bound of the two-sided 90% CI for the mean differences between lenalidomide and placebo was below 10 ms.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.

Excretion Elimination is primarily renal.

Approximately 82% of the radioactive dose was excreted as lenalidomide in the urine within 24 hours.

Hydroxy-lenalidomide and N-acetyl-lenalidomide represented 4.6% and 1.8% of the excreted dose, respectively.

The renal clearance of lenalidomide exceeds the glomerular filtration rate.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Following single and multiple doses of REVLIMID in patients with MM or MDS, the maximum plasma concentrations occurred between 0.5 and 6 hours post-dose. The single and multiple dose pharmacokinetic disposition of lenalidomide is linear with AUC and C max values increasing proportionally with dose.

Multiple doses of REVLIMID at the recommended dosage does not result in drug accumulation. Administration of a single 25 mg dose of REVLIMID with a high-fat meal in healthy subjects reduces the extent of absorption, with an approximate 20% decrease in AUC and 50% decrease in C max. In the trials where the efficacy and safety were established for REVLIMID, the drug was administered without regard to food intake.

REVLIMID can be administered with or without food. The oral absorption rate of lenalidomide in patients with MCL is similar to that observed in patients with MM or MDS. Distribution In vitro [14 C]-lenalidomide binding to plasma proteins is approximately 30%. Lenalidomide is present in semen at 2 hours (1379 ng/ejaculate) and 24 hours (35 ng/ejaculate) after the administration of REVLIMID 25 mg daily.

Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL. Metabolism Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are 5-hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation.

Excretion Elimination is primarily renal. Following a single oral administration of [14 C]-lenalidomide 25 mg to healthy subjects, approximately 90% and 4% of the radioactive dose was eliminated within ten days in urine and feces, respectively. Approximately 82% of the radioactive dose was excreted as lenalidomide in the urine within 24 hours.

Hydroxy-lenalidomide and N-acetyl-lenalidomide represented 4.6% and 1.8% of the excreted dose, respectively. The renal clearance of lenalidomide exceeds the glomerular filtration rate. Specific Populations Renal Impairment: Eight subjects with mild renal impairment (creatinine clearance (CLcr) 50 to 79 mL/min calculated using Cockcroft-Gault), 9 subjects with moderate renal impairment (CLcr 30 to 49 mL/min), 4 subjects with severe renal impairment (CLcr < 30 mL/min), and 6 patients with end stage renal disease (ESRD) requiring dialysis were administered a single 25 mg dose of REVLIMID.

Three healthy subjects of similar age with normal renal function (CLcr > 80 mL/min) were also administered a single 25 mg dose of REVLIMID. As CLcr decreased, half-life increased and drug clearance decreased linearly. Patients with moderate and severe impairment had a 3-fold increase in half-life and a 66% to 75% decrease in drug clearance compared to healthy subjects.

Patients on hemodialysis (n=6) had an approximate 4.5-fold increase in half-life and an 80% decrease in drug clearance compared to healthy subjects. Approximately 30% of the drug in body was removed during a 4-hour hemodialysis session. Adjust the starting dose of REVLIMID in patients with renal impairment based on the CLcr value [see Dosage and Administration (2.6)].

Hepatic Impairment: Mild hepatic impairment (defined as total bilirubin > 1 to 1.5 times upper limit normal (ULN) or any aspartate transaminase greater than ULN) did not influence the disposition of lenalidomide. No pharmacokinetic data is available for patients with moderate to severe hepatic impairment. Other Intrinsic Factors: Age (39 to 85 years), body weight (33 to 135 kg), sex, race, and type of hematological malignancies (MM, MDS or MCL) did not have a clinically relevant effect on lenalidomide clearance in adult patients.

Drug Interactions Co-administration of a single dose or multiple doses of dexamethasone (40 mg) had no clinically relevant effect on the multiple dose pharmacokinetics of REVLIMID (25 mg). Co-administration of REVLIMID (25 mg) after multiple doses of a P-gp inhibitor such as quinidine (600 mg twice daily) did not significantly increase the Cmax or AUC of lenalidomide.

Co-administration of the P-gp inhibitor and substrate temsirolimus (25 mg),with REVLIMID (25 mg) did not significantly alter the pharmacokinetics of lenalidomide, temsirolimus, or sirolimus (metabolite of temsirolimus). In vitro studies demonstrated that REVLIMID is a substrate of P-glycoprotein (P-gp). REVLIMID is not a substrate of human breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) transporters MRP1, MRP2, or MRP3, organic anion transporters (OAT) OAT1 and OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), organic cation transporters (OCT) OCT1 and OCT2, multidrug and toxin extrusion protein (MATE) MATE1, and organic cation transporters novel (OCTN) OCTN1 and OCTN2.

Lenalidomide is not an inhibitor of P-gp, bile salt export pump (BSEP), BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, or OCT2. Lenalidomide does not inhibit or induce CYP450 isoenzymes. Also, lenalidomide does not inhibit bilirubin glucuronidation formation in human liver microsomes with UGT1A1 genotyped as UGT1A1*1/*1, UGT1A1*1/*28, and UGT1A1*28/*28.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Revlimid · Celgene Corporation [US FDA-approved label, version 41, March 24, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .